Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease.

Текст сохранён. Часть иллюстраций пока доступна только в первоисточнике; загрузка будет проверена повторно.

Main Text

Conventional Gene Therapy

Traditionally, gene therapy relies on viral-based delivery of a protein-coding gene that either semi-randomly integrates into the genome (for retroviruses and lentiviruses) or remains as extrachromosomal DNA copy (for adeno-associated virus [AAV]). 1 , 2 , 3 These forms of gene therapy usually use overexpression of a protein that is missing or mutated in human disease. Lentiviral gene therapy has the advantage of being highly efficient and causing long-term efficacy. A drawback of lentiviral gene therapy is the lack of control of the location at which the virus integrates into the host genome, with the risk of insertional mutagenesis. By optimizing the lentiviral backbone and by controlling the number of viral copies, it has been demonstrated in multiple clinical trials that lentiviral gene therapy is safe provided that it is used with the proper precautions. 2 , 4 AAV-mediated gene therapy does not rely on integration into the host genome but instead involves delivery of a DNA episome to the nucleus. It is therefore considered to have a lower risk of genotoxicity compared to lentiviral gene therapy. However, episomal copies of AAV DNA are lost upon cell division, resulting in loss of efficacy. This restricts AAV gene therapy to nondividing cells. In addition, pre-existing immunity to AAV capsid proteins occurs in a significant percentage of the human population and precludes eligibility for the treatment. 5 Acquired immunity after a single AAV-mediated gene therapy treatment occurs invariably in patients and precludes eligibility for a second treatment. In both forms of gene therapy, cDNA overexpression can only be used when dosage effects of the transgene product do not apply. Although the desired average number of gene copies can be approached via the viral titer, it is not possible to precisely control this using viral-based overexpression.

Basics of Gene Editing

Developments in recent years have enabled the seamless engineering of the human genome using a variety of tools collectively termed gene editing. Precision gene editing strategies allow alteration of the genome of cells at specific loci to generate targeted genomic changes, which are being exploited for multiple applications in medicine. We first introduce the basics of gene editing and then summarize the major challenges for their clinical implementation. Gene editing tools that are currently under investigation in clinical trials include zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered interspaced short palindromic repeats (CRISPR) in combination with CRISPR-associated protein (Cas). For a detailed comparison between these tools, we refer to previously published reviews. 6 , 7 In short, target site recognition occurs by sequence-specific DNA-binding proteins (in the case of ZFNs and TALENs) or by a short stretch of RNA termed single guide RNA (sgRNA; in the case of CRISPR-Cas). Current clinical applications of gene editing rely on the introduction of double-strand DNA breaks (DSBs), mediated by Fok-1 (in the case of ZFNs or TALENs) or by Cas nucleases (in the case of CRISPR-Cas) and the introduction of desired genomic alterations through the cell’s endogenous DNA repair mechanisms. Two major DNA repair pathways are being exploited to conduct targeted genomic changes in clinical trials: (1) gene editing through homology-directed repair (HDR) used to replace a pathogenic variant or insert foreign DNA elements to restore the wild-type (WT) expression of a missing (or truncated) gene; and (2) non-homologous end joining (NHEJ) used to remove DNA elements leading to aberrant expression of genes or to gain a therapeutic function.

In contrast to traditional strategies for gene therapy, gene editing provides more versatile tools for gene therapy, for example to precisely correct point variants, 8 , 9 to place an extra, healthy gene copy at a safe genomic location of choice (a safe harbor: a location in the human genome at which integration of a gene is not harmful), 10 , 11 or to disrupt a gene. This would, for example, enable the restoration of endogenous expression levels following precise correction of the disease-associated variant within the natural locus, which would be especially important for gene products for which a correct dosage is required. It would also increase control of integration sites of a cDNA by choosing appropriate safe harbor locations. Such locations also should provide efficient transcription of the transgene by providing a favorable epigenetic environment consisting of euchromatin. Examples of safe harbor locations in the human genome are the albumin, AAVS1 , and the CCR5 loci.

On-Target or Off-Target?

Although the technology for gene editing is rapidly evolving, there are still important challenges for its clinical implementation. First, undesired editing of genomic regions can occur as a side effect of gene editing. 7 This can be off-target, i.e., the introduction of a DNA break outside the genomic region of choice due to the targeting of the gene editing machinery to a chromosomal location that carries sequence similarity to the region of interest. In this scenario, genes or regulatory regions other than the targeted gene can be modified, resulting in undesired downstream effects. Undesired events may include insertions, deletions, and chromosomal translocations. 12 , 13 Undesired variants can also be generated on-target, i.e., unintended modification of the genomic region of interest. In this scenario, regulatory elements within the gene of interest may be unintentionally changed. This may include elements involved in promoter activity, splicing, mRNA stability, protein translation, or microRNA (miRNA) genes (that are often present in introns or untranslated regions). The CRISPR-Cas9 system is inherently more prone to off-target effects compared to ZFNs or TALENs, because target site recognition in CRISPR-Cas9 relies on RNA-DNA interaction of only short stretches, and the RNA-DNA interaction allows some mismatches. In contrast, ZFNs and TALENs depend on highly specific protein-DNA interactions that allow fewer mismatches. 14 This has promoted much research directed toward enhancing the performance of CRISPR-Cas-based gene editing with respect to specificity and nuclease activity (see below). Methods to detect undesired events in gene editing often rely on in silico predictions, followed by analyses of predicted off-target events. This is not necessarily sufficient for clinical application, and unbiased analysis based on next-generation sequencing is expected to become an important tool in the future. For a more extensive discussion on off-target effects, see Broeders et al., 7 Kim et al., 15 Manghwar et al., 16 and Pattanayak et al. 17

Delivery of Gene Editing

The delivery of gene editing tools is a crucial aspect when it comes to clinical implementation. Two routes can be distinguished: ex vivo and in vivo delivery. 18 , 19 In ex vivo delivery, autologous or allogeneic cells are modified by gene editing outside the patient, and gene-modified cells are transplanted into the patient. Any route of administration of gene editing machinery can be applied ex vivo , such as transfection, nucleofection, or (viral) transduction. Ex vivo gene editing allows quality control prior to treatment. In particular, undesired off-target and on-target events can be monitored. Note that quality control can be performed on bulk generations of cells. Rare undesired events that occur in only a few cells and that might cause cellular transformation will be difficult to detect. Alternatively, this method involves an extra complication: the engraftment of (stem) cells. For example, maintaining engraftment potential and viability of the cell of interest can be challenging. Clinically, the most advanced forms of ex vivo gene editing involve T cells and hematopoietic stem cells (HSCs). In in vivo gene editing, gene editing tools are applied directly to the organism. Vehicles for delivery include AAV, lipid nanoparticles (LNPs), gold nanoparticles (GNPs), or cell-penetrating peptides (CPPs). The delivery method in in vivo gene editing is crucial for its safety. 20 When gene editing components are delivered in vivo via vehicles that remain present for an extended period, for example via AAV, there is a cumulative risk of undesired genotoxic events that can last for the time that the AAV remains present, which has been estimated to last for a period of 10 years or longer. 1 In contrast, when delivered as RNA or protein, there is only short-term exposure and a reduced risk of genotoxicity.

For in vivo gene editing, immunity against the delivery vehicle and the gene editing components are important considerations. 21 Both pre-existing and acquired immunity should be considered. The AAV delivery vehicle is subject to pre-existing immunity in a significant proportion of the population. 1 In addition, preexisting immunity to Cas9 protein from several species has been reported in several studies. This may neutralize the therapy or induce adverse events. 21 , 22 , 23

In summary, the safety and efficacy of gene editing technology for the treatment of human disease depend on multiple factors, including the choice of the gene editing method, being either ex vivo or in vivo , the gene editing technique, target site selection, delivery method, and target tissue.

Gene Editing 2.0: Preclinical Developments

Technological developments are ongoing to improve gene editing tools with respect to specificity, efficiency, and versatility. These have been extensively described by us and others in recent reviews 7 , 24 , 25 , 26 and are only briefly mentioned here.

First, variations of the original CRISPR-Cas9 method have been designed. These include the following: homology-independent targeted integration (HITI) for generating a knockin via NHEJ without involvement of HDR; 27 microhomology-mediated end joining (MMEJ)-dependent knockin, which is based on the presence of short stretches of homology that are utilized by the MMEJ DNA repair pathway; 28 base editing, 29 a mismatch repair- or base excision repair-dependent pathway in which a natural cytidine or adenosine deaminase (ADA) is coupled to a catalytically dead Cas9 (dCas9) to convert cytidine to uridine (which is replicated as thymidine), or to convert adenine to inosine, which is replicated as guanine; and prime editing, 30 in which a Cas9 nicking variant is used that introduces single stranded DNA breaks and that is coupled to reverse transcriptase to enable a wide variety of genomic changes. Second, other natural and engineered Cas9 variants have been identified and developed with distinct and/or enhanced targeting properties, including Cas12a (Cpf1), Cas12b (C2c1), FokI fused to dCas9, 31 Cas9-HF1, 32 eSpCs9, 33 evoCas9, 34 and HypaCas9. 35 Third, Cas9 variants with distinct protospacer-adjacent motif (PAM) recognition sites have been generated, including VQR and VRER variants, xCas9, and SpCas9-NG. 36 And fourth, sgRNAs have been modified with respect to their length, structure, and chemistry to reduce off-target properties. 37 , 38 , 39 These promising developments need future work to evaluate their suitability for clinical testing.

Scope of This Review

Whereas there have been numerous applications of gene editing in preclinical studies, information on clinical applications of gene editing is scattered in the literature. In this review, we present a comprehensive overview of current clinical trials using gene editing strategies for the treatment of human disease, and include selected preclinical examples. For more extensive overviews of preclinical studies, we refer to excellent reviews. 40 , 41 In addition, in this review, we focus on gene editing in somatic cells, and we refer to other recent reviews and opinion articles for editing the germline. 42 , 43 , 44 Thus far, precision gene editing has entered the clinic for the treatment of cancer immunotherapy, viral infections, and inherited hematologic, metabolic, and eye disorders ( Table 1 ). These trials along with the underlying strategies are described in more detail below. Table 1 Current Clinical Trials Involving Gene Editing Title Tool Status Country Delivery ID Ref. Cancer Immunotherapy PD-1 knockout engineered T cells for advanced esophageal cancer CRISPR-Cas9 completed China ex vivo NCT03081715 61 PD-1 knockout engineered t cells for metastatic non-small cell lung cancer CRISPR-Cas9 active, not recruiting China ex vivo NCT02793856 62 Therapeutic vaccine plus PD-1 knockout in prostate cancer treatment CRISPR-Cas9 recruiting China ex vivo NCT03525652 63 PD-1 knockout EBV-CTLs for advanced stage Epstein-Barr virus (EBV) associated malignancies CRISPR-Cas9 recruiting China ex vivo NCT03044743 64 CD19 CAR and PD-1 knockout engineered T cells for CD19 positive malignant B cell derived leukemia and lymphoma N.S. not yet recruiting China ex vivo NCT03298828 82 Study of PD-1 gene-knocked out mesothelin-directed CAR-T cells with the conditioning of PC in mesothelin positive multiple solid tumors CRISPR-Cas9 recruiting China ex vivo NCT03747965 83 CAR T and PD-1 knockout engineered T cells for esophageal cancer N.S. recruiting China ex vivo NCT03706326 84 Anti-MUC1 CAR T cells and PD-1 knockout engineered T cells for NSCLC N.S. recruiting China ex vivo NCT03525782 85 CRISPR (HPK1) edited CD19-specific CAR-T cells (XYF19 CAR-T Cells) for CD19 + leukemia or lymphoma CRISPR-Cas9 recruiting China ex vivo NCT04037566 86 Study of UCART19 in pediatric patients with relapsed/refractory B acute lymphoblastic leukemia (PALL) TALEN active, not recruiting US/EU/UK ex vivo NCT02808442 103 Dose escalation study of UCART19 in adult patients with relapsed/refractory B cell acute lymphoblastic leukaemia (CALM) TALEN active, not recruiting US/EU/UK/Japan ex vivo NCT02746952 104 Safety and efficacy of ALLO-501 anti-CD19 allogeneic CAR T cells in adults with relapsed/refractory large B cell or follicular lymphoma (ALPHA) TALEN recruiting US ex vivo NCT03939026 105 Safety and efficacy of ALLO-715 BCMA allogenic CAR T cells in in adults with relapsed or refractory multiple myeloma (UNIVERSAL) TALEN recruiting US ex vivo NCT04093596 106 A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19/ALLO-501 TALEN enrolling by invitation US/EU/UK/Japan ex vivo NCT02735083 107 A study evaluating UCART019 in patients with relapsed or refractory CD19 + leukemia and lymphoma CRISPR-Cas9 recruiting China ex vivo NCT03166878 112 A safety and efficacy study evaluating CTX110 in subjects with relapsed or refractory B cell malignancies CRISPR-Cas9 recruiting US/Australia/Germany ex vivo NCT04035434 115 A safety and efficacy study evaluating CTX120 in subjects with relapsed or refractory multiple myeloma CRISPR-Cas9 recruiting US/Australia ex vivo NCT04244656 116 CTA101 UCAR-T cell injection for treatment of relapsed or refractory CD19 + B cell acute lymphoblastic leukemia CRISPR-Cas9 recruiting China ex vivo NCT04154709 117 Phase I study of UCART22 in patients with relapsed or refractory CD22 + B cell acute lymphoblastic leukemia (BALLI-01) TALEN recruiting US ex vivo NCT04150497 118 CTA101 in the treatment of relapsed or refractory diffuse large B cell lymphoma CRISPR-Cas9 not yet recruiting China ex vivo NCT04026100 119 A feasibility and safety study of universal dual specificity CD19 and CD20 or CD22 CAR-T cell immunotherapy for relapsed or refractory leukemia and lymphoma CRISPR-Cas9 recruiting China ex vivo NCT03398967 120 Study evaluating safety and efficacy of UCART123 in patients with acute myeloid leukemia (AMELI-01) TALEN recruiting US ex vivo NCT03190278 121 Study evaluating safety and efficacy of UCART targeting CS1 in patients with relapsed/refractory multiple myeloma (MELANI-01) TALEN recruiting US ex vivo NCT04142619 122 Anti-CD19 U-CAR-T cell therapy for B cell hematologic malignancies N.S. not yet recruiting China ex vivo NCT04264039 123 Anti-CD7 U-CAR-T cell therapy for T/NK cell hematologic malignancies N.S. not yet recruiting China ex vivo NCT04264078 124 Efficacy and safety evaluation of BCMA-UCART N.S. recruiting China ex vivo NCT03752541 125 Safety and efficacy evaluation of CD19-UCART N.S. recruiting China ex vivo NCT03229876 126 The clinical study of CD19 UCAR-T cells in patients with B cell acute lymphoblastic leukemia (B-ALL) N.S. recruiting China ex vivo NCT04166838 127 NY-ESO-1-redirected CRISPR (TCRendo and PD1) edited t cells (NYCE T cells) CRISPR-Cas9 terminated US ex vivo NCT03399448 133 Study of CRISPR-Cas9 mediated PD-1 and TCR gene-knocked out mesothelin-directed CAR-T cells in patients with mesothelin positive multiple solid tumors CRISPR-Cas9 recruiting China ex vivo NCT03545815 134 Cell therapy for high risk T cell malignancies using CD7-specific CAR expressed on autologous T cells CRISPR-Cas9 not yet recruiting US ex vivo NCT03690011 144 Cervical Cancer Study of molecular-targeted therapy using zinc finger nuclease in cervical precancerous lesions ZFN N.S. China in vivo NCT02800369 160 Study of targeted therapy using transcription activator-like effector nucleases in cervical precancerous lesions TALEN N.S. China in vivo NCT03226470 161 A safety and efficacy study of TALEN and CRISPR/Cas9 in the treatment of HPV-related cervical intraepithelial neoplasia CRISPR-Cas9 TALEN N.S. China in vivo NCT03057912 162 HIV Infection and AIDS Autologous T cells genetically modified at the CCR5 gene by zinc finger nucleases SB-728 for HIV ZFN completed US ex vivo NCT00842634 189 Phase 1 dose escalation study of autologous t cells genetically modified at the CCR5 gene by zinc finger nucleases in HIV-infected patients ZFN completed US ex vivo NCT01044654 190 Repeat doses of SB-728mR-T after cyclophosphamide conditioning in HIV-infected subjects on HAART ZFN completed US ex vivo NCT02225665 191 A phase I study of T cells genetically modified at the CCR5 gene by zinc finger nucleases SB-728mR in HIV-infected patients ZFN completed US ex vivo NCT02388594 192 Dose escalation study of cyclophosphamide in HIV-infected subjects on HAART receiving SB-728-T ZFN completed US ex vivo NCT01543152 193 CCR5-modified CD4 + T cells for HIV infection (TRAILBLAZER) ZFN recruiting US ex vivo NCT03666871 194 Study of autologous T cells genetically modified at the CCR5 gene by zinc finger nucleases in HIV-infected subjects ZFN completed US ex vivo NCT01252641 195 Long-term follow-up of HIV subjects exposed to SB-728-T or SB-728mR-T ZFN enrolling by invitation US ex vivo NCT04201782 197 Safety study of zinc finger nuclease CCR5-modified hematopoietic stem/progenitor cells in HIV-1 infected patients ZFN active, not recruiting US ex vivo NCT02500849 203 Safety of transplantation of CRISPR CCR5 modified CD34 + cells in HIV-infected subjects with hematological malignances CRISPR-Cas9 recruiting China ex vivo NCT03164135 204 CD4 CAR+ ZFN-modified T cells in HIV therapy ZFN active, not recruiting US ex vivo NCT03617198 206 β-thalassemia and Sickle Cell Disease A safety and efficacy study evaluating CTX001 in subjects with transfusion-dependent β-thalassemia CRISPR-Cas9 recruiting US/Canada/EU/UK ex vivo NCT03655678 263 A study to assess the safety, tolerability, and efficacy of ST-400 for treatment of transfusion-dependent beta-thalassemia (TDT) ZFN active, not recruiting US ex vivo NCT03432364 264 A safety and efficacy study evaluating CTX001 in subjects with severe sickle cell disease CRISPR-Cas9 recruiting US/Canada/EU ex vivo NCT03745287 265 A study to assess the safety, tolerability, and efficacy of BIVV003 for autologous hematopoietic stem cell transplantation in patients with severe sickle cell disease (BIVV003) ZFN recruiting US ex vivo NCT03653247 266 A long-term follow-up study in subjects who received CTX001 CRISPR-Cas9 enrolling by invitation US/EU ex vivo NCT04208529 267 iHSCs with the gene correction of HBB intervent subjests with β-thalassemia mutations CRISPR-Cas9 not yet recruiting N.S. ex vivo NCT03728322 280 Hemophilia Ascending dose study of genome editing by zinc finger nuclease therapeutic SB-FIX in subjects with severe hemophilia B ZFN active, not recruiting US in vivo NCT02695160 289 Mucopolysaccharidoses Ascending dose study of genome editing by the zinc finger nuclease (ZFN) therapeutic SB-318 in subjects with MPS I ZFN active, not recruiting US in vivo NCT02702115 319 Ascending dose study of genome editing by the zinc finger nuclease (ZFN) therapeutic SB-913 in subjects with MPS II ZFN active, not recruiting US in vivo NCT03041324 320 Leber’s Congenital Amaurosis Single ascending dose study in participants with LCA10 CRISPR-Cas9 recruiting US in vivo NCT03872479 329 N.S., not specified.

Gene Editing in Cancer Immunotherapy

Adoptive cell therapy (ACT) is a cellular form of cancer immunotherapy involving T cells with anti-tumor activity 45 that are expanded ex vivo , ex vivo genetically engineered or not, and applied to the patient via the circulation. Three major types of lymphocytes are used in ACT: (1) tumor-infiltrating lymphocytes (TILs), which are T cells that are isolated from tumors; and peripheral blood T lymphocytes that are (2) selected for tumor reactivity and expanded ex vivo before reinfusion or (3) genetically modified ex vivo with a transgenic T cell receptor (tTCR) or a chimeric antigen receptor (CAR) to target tumor cells. 46 ACT has been combined with ex vivo gene editing in a number of clinical trials, as discussed below.

Immune Checkpoint Knockout

Immune checkpoints are immune modulatory signals that can dampen the amplitude and quality of the immune response. Their physiological function is to prevent overstimulation of the immune system in order to maintain self-tolerance. A hallmark of cancer cells is their ability to exploit immune checkpoints to evade attack by the immune system. Cancer cells or their microenvironment can achieve this by activating immune checkpoints via overexpression of ligands or receptors that regulate the function of T cells. 47 , 48 In this way, cancer cells escape immune surveillance. To exploit this property of cancer cells for anti-cancer therapy, monoclonal antibodies have been developed that block natural immune checkpoints (present on T cells) or their ligands (present on cancer cells or in their micro-environment). This has revolutionized the field of anti-cancer therapy. 49 Examples include PD-1 and PD-L1 inhibitors, which have shown impressive results for treating different types of cancer at an advanced stage, 50 , 51 especially melanoma. 52 PD-1, encoded by the PDCD1 gene, is a cell-surface receptor expressed on cytotoxic T cells that downregulates T cell activity upon interaction with its ligand PD-L1, which is overexpressed on malignant cells and cells in the tumor micro-environment. 48 In spite of general good tolerability, systemic administration of immune checkpoint inhibitors can result in autoimmune phenomena, referred to as immune-related adverse events (IRAEs). 53 IRAEs occur in up to 70% of patients receiving PD-1 and PD-L1 inhibitors 50 , 51 and have been described in multiple organ systems. Steroids might be used to manage IRAEs, but the extent of interference with immunotherapy is unknown. 53

Knocking out immune checkpoint molecules in tumor-specific T cells is a promising strategy for ACT to circumvent systemic effects of checkpoint inhibition ( Figure 1 ). When applied to total T cells harvested from patients, knocking out immune checkpoint molecules should render these less susceptible to immune inhibitory signals upon reinfusion. However, such an approach involves a heterogeneous T cell population rather than tumor-specific T cells. One solution to this problem would be to increase tumor specificity of circulating T cells in vitro by exposure to tumor-associated antigens. 54 Figure 1 Effect of PD-1 Knockout in Cytotoxic T Cells Cytotoxic T cells are able to recognize tumor cells via the T cell receptor (TCR). This receptor recognizes an antigen that is presented on potential target cells by the MHC. Binding results in T cell activation through signal transduction. The activated T cell will expand and exert its cytotoxic effector function on target cells, thus inducing apoptosis. If the target cell expresses PD-L1, it can interact with PD-1 that is expressed on the surface of the T cell. This will lead to activation of PD-1, one of the immune checkpoint molecules, resulting in inhibition of the T cell’s cytotoxic activity. If PD-1 is disrupted in the cytotoxic T cell, PD-L1 expressed from the tumor cell can no longer interact with the T cell and inhibition of T cell cytotoxicity is prevented. In this scenario, PD-1 disruption prevents escape of tumor cells from attack by cytotoxic T cells. Red indicates the result of intervention.

Due to the impressive clinical results from checkpoint inhibitors and TILs to treat melanoma, this type of cancer was chosen in the initial preclinical studies on applying immune checkpoint knockout (KO) in ACT using ex vivo gene editing. Promising in vitro results were reported from co-cultures of human tumor-specific T cells in which PD-1 was disrupted with melanoma cell lines, 55 , 56 and more recently by infusing PD-1 knockout T cells cells into mice that had been xenografted with human melanoma cells. 57 An improved cytotoxic effect of tumor-specific T cells following PD-1 knockout was also reported in preclinical studies of other cancer models, such as in a cultured gastric cancer cell line, 56 and in mice subcutaneously injected with either a fibrosarcoma cell line, 58 a multiple myeloma (MM) cell line, 59 or a liver cancer cell line. 60 Academic hospitals have been recruiting patients in clinical trials to investigate autologous, PD-1 knocked out T cells for the treatment of multiple types of cancer, including solid tumors arising from the esophagus, 61 lung, 62 prostate, 63 and Epstein-Barr-related neoplasms. 64 The publicly provided information is scarce. Presumably, as described for preclinical studies, these T cells have been manipulated ex vivo to enhance their tumor specificity, but this has not been specified. Recently, the results for PD-1-edited T cells in metastatic lung carcinoma patients were published. 65 Although no methods for increasing the tumor specificity of T cells was described, no severe adverse events were reported in 12 patients after a median follow-up time of 47.1 weeks. Despite the treatment, 10 patients progressed, and only 2 responded transiently. Although not designed to investigate the therapeutic effect, these results were somewhat disappointing and are possibly caused by inadequate levels of tumor-specific T cells.

Another method of generating tumor-specific T cell clones is the ex vivo expansion of T cells that are isolated from tumor tissue, so-called TILs. Although not yet clinically applied, PD-1 knockout in TILs has resulted preclinically in an improved anti-tumor effect in vitro 55 and in vivo . 58

Innate immune cells such as dendritic cells (DCs) and natural killer (NK) cells are also target cells for the development of immunotherapy against cancer. 66 Importantly, NK cells have also been shown to express several immune checkpoint inhibitors. 67 An example of recent preclinical developments is the knockout of the NKp46 and CIS checkpoint genes in primary human NK cells. 68 , 69 Although gene-edited innate immune cells have not yet reached clinical trials, these efforts illustrate the ongoing work that might promote their clinical development.

Immune Checkpoint Knockout in Genetically Engineered T Cells: tTCR-T and CAR-T cells

Besides the isolation of T cells with enhanced anti-tumor activity from patients, it is also possible to induce tumor specificity in T cells using genetic engineering (using viral transduction or gene editing). Such redirected T cells can be generated by forced expression of receptors with enhanced specificity for a tumor-associated antigen, such as tTCRs or CARs. 70 , 71 tTCRs are transgenic forms of naturally occurring receptors isolated from tumor-specific T cells and depend on the major histocompatibility complex (MHC) for efficient antigen recognition. 72 CARs are synthetic receptors that do not depend on MHC for efficient antigen binding. 73 To avoid negative regulation by tumors, immune checkpoint inhibition (using antibodies) or knock out (using gene editing) are also worthwhile strategies in tTCR-T cells and CAR-T cells.

The concept of immune checkpoint knockout in redirected T cells has been demonstrated in vitro and in vivo , both for tTCR-T cells 74 and CAR-T cells. 75 , 76 , 77 , 78 , 79 Improved antitumor reactivity of redirected T cells after PD-1 disruption was observed in a range of preclinical cancer models, for example, models of melanoma, 74 hepatocellular carcinoma, 75 glioma, 76 , 79 breast cancer, 77 and erytroleukemia. 78 In addition, encouraging clinical results have already been obtained by combining CAR-T cells with immune checkpoint inhibitors. 80 , 81 Using gene editing, PD-1 knockout in CAR-T cells that were redirected against the B cell marker cluster of differentiation 19 (CD19) 82 and membrane proteins mesothelin 83 and MUC1, 84 , 85 which are upregulated in a range of malignancies, are investigated in clinical trials for the treatment of B cell leukemia/lymphoma, 82 multiple mesothelin-positive solid tumors (such as pancreatic cancer, cholangiocarcinoma cancer, and ovarian cancer), 83 esophageal cancer, 84 and lung cancer. 85 One trial investigates the infusion of CAR-T cells carrying an HPK1 knockout in patients with relapsed or refractory CD19 + leukemia or lymphoma. 86 HPK1 is a protein kinase that was found to suppress the anti-tumor response of T cells by attenuating TCR signaling. 87 In addition, HPK1 exerts T cell inhibitory effects downstream of E prostanoid receptor activation by prostaglandin E2, a metabolic byproduct that is overproduced by cancers such as non-small-cell lung carcinomas. 88 , 89 Mice with a kinase-dead HPK1 showed improved anti-tumor 89 , 90 and antiviral responses. 90

Disruption of other molecules with immunomodulatory effects in ACT has been performed in preclinical studies, but no clinical trials are currently open. For example, infusion of cytotoxic T cells in which the immune checkpoint gene CTLA-4 was disrupted resulted in decreased tumor growth compared to infusion of non-edited counterparts in mice that were xenografted subcutaneously with bladder cancer cell lines 91 or colon cancer cell lines. 92 In addition, the anti-tumor effect of CAR-T cells against a human glioma cell line that was subcutaneously engrafted in mice was enhanced upon knockout of DGK , 93 which encodes an intracellular enzyme that negatively regulates TCR signaling. 94 In contrast, disruption of the immune checkpoint gene LAG-3 in CAR-T cells did not result in an enhanced anti-tumor effect in mice subcutaneously engrafted with a human lymphoma cell line, 95 suggesting that the choice of immune checkpoint gene is important to design an efficient treatment.

Universal ACT

So far, we discussed autologous T cell therapies. However, this is not always feasible for every patient. 96 The establishment of universal, allogeneic ACT might be an attractive alternative, because such “off-the-shelf” therapy would overcome the high costs and experimental burden of manufacturing a custom-made autologous or histocompatibility leukocyte antigen (HLA)-matched allogeneic therapy for every patient. For such therapy, the risks of graft-versus-host disease (GvHD) and graft rejection by the patients’ immune system for universal ACT must be addressed. The strategies used involve knockout of the TCR to prevent GvHD, and knockout of human leukocyte antigen (HLA) genes to prevent graft rejection by the host immune system. 97 , 98 Clinical studies and preclinical examples are discussed below.

In vitro studies showed that anti-CD19 CAR-T cells, which target B cells, tolerated ZFN-mediated knockout of the TCR, as assessed by cell proliferation and their ability to lyse target cells. 99 In addition, in vivo application of such cells demonstrated an anti-leukemic response in mice that were intravenously injected with a lymphoma cell line that was similar or better compared to non-edited cells. 100 , 101 The feasibility of clinical implementation of such a strategy was illustrated by a study in which two therapy-refractory pediatric patients with acute lymphoblastic leukemia (ALL) were treated with allogeneic anti-CD19 CAR-T cells from unselected donors 102 that had been engineered in vitro using TALENs in two ways. First, expression of the endogenous αβ TCR was disrupted by targeting the constant region of the TCR α chain. Second, CD52 was knocked out with the following rationale. CD52 is expressed on T cells, and anti-CD52 antibodies (alemtuzumab) are part of the conditioning regimen prior to allogeneic HSC transplantation to reduce the risk of graft rejection by the host’s lymphocytes. To prevent alemtuzumab from attacking anti-CD19 CAR-T cells, these cells were made resistant by knockout of CD52 . Despite development of grade 2 GvHD in one of the patients, the results of this trial indicated an ongoing disease-free survival of the two patients of 12 and 18 months after the start of therapy. 102 These results suggest that off-the-shelf allogeneic CAR-T cells therapy is feasible, and that adverse events such as GvHD are manageable. This exact strategy is adopted in clinical trials investigating universal CAR-T cells in pediatric or adult B cell ALL, 103 , 104 B cell lymphoma, 105 and MM patients. 106 The long-term effects of two of these products are investigated in a separate trial. 107

To reduce the risk of graft rejection by the host immune system, HLA genes have been disrupted in donor T cells. 108 , 109 , 110 , 111 Notably, CRISPR-Cas9-mediated triple KO of the T cell receptor α constant ( TRAC ) locus , an HLA complex gene ( B2M ), and an immune checkpoint gene ( PDCD1 ) was used to potentiate the anti-tumor effect of CAR-T cells against multiple targets in mouse models, for example in mice intravenously injected with a B cell ALL cell line, 109 in mice intraperitoneally injected with a lymphoma cell line, 110 and in mice intracerebrally injected with a glioma cell line. 111 In one active clinical trial both the endogenous TCR and HLA complex are knocked out in anti-CD19 CAR-T cells for treating of B cell leukemia and lymphoma. 112

In another concept, a tumor-targeting CAR or tTCR is inserted into the TRAC locus using CRISPR-Cas9-mediated HDR. This yields two effects: knockout of the endogenous TCR, and knockin of the CAR/tTCR. In a preclinical study, a CD19-directed CAR was inserted into the TRAC locus in human T cells by HDR using CRISPR-Cas9. 113 When these CAR-T cells were administered to a mouse model of ALL, an improved anti-leukemic response was observed that resulted in prolonged survival compared to conventionally generated CAR-T cells. 113 A similar strategy proved feasible for inserting a tTCR directed against the immunogenic cancer antigen NY-ESO-1 in the TRAC locus. 114 This strategy is adopted in two clinical trials for patients with B cell malignancies 115 or MM, 116 in which the endogenous TCR is disrupted by knockin of an anti-CD19 or anti-BCMA CAR in the TCR locus of allogeneic T cells, respectively. In addition, the HLA complex is disrupted by knockout of the B 2M gene.

Additional clinical studies are planned, in which infusion of universal CAR-T cells (engineered using TALENs or CRISPR-Cas9) will be investigated for the treatment of B cell ALL or lymphoma, 117 , 118 , 119 , 120 acute myeloid leukemia (AML), 121 and multiple myeloma. 122 No molecular details are provided for these trials. Five more clinical trials are active or planned that will investigate universal CAR-T cells in hematological malignancies, but no information on the applied gene editing platform has been provided. 123 , 124 , 125 , 126 , 127

A challenging application in one of the aforementioned trials is the treatment of AML with ACT, because molecular targets of leukemic cells in AML are also expressed in HSCs. As a result, ACT will attack the host’s HSCs and impair hematopoiesis. 128 Indeed, severe myelotoxicity, leading to prolonged pancytopenia, was seen in preclinical studies using CAR-T cells directed at CD33 129 and CD123. 130 One possible strategy to circumvent this problem would be to co-transplant HSCs in which the target molecule is knocked out together with the CAR-T cells. As the CAR-T cells will attack the leukemic cells and unmodified recipient HSCs, the gene-edited donor HSCs will not be targeted anymore and will repopulate the bone marrow. This strategy has been proven feasible in a mouse model for AML, in which anti-CD33 CAR-T cells along with CD33-edited HSCs were used. 131 The leukemic cells responded to anti-CD33 CAR-T cell treatment, while myelotoxicity was selectively mitigated in mice transplanted with CD33-edited HSCs. An ongoing clinical trial investigates universal CAR-T cells in refractory or relapsed AML, but it does not include a method to mitigate the possible myelotoxic effect of CAR-T cells. 121

Endogenous TCR Knockout in Autologous ACT

Above we described the knockout of the endogenous TCR in allogeneic ACT products to prevent GvHD. However, there is also a rationale for knocking out endogenous TCR components in autologous ACT. The reason for this is that the endogenous TCR can interfere with the function of the tTCR/CAR, either by competing for cell surface expression, or by dimerization to form a novel hybrid compound TCR that might cause autoimmune reactions. 132 Knockout of endogenous TCR components in autologous ACT cells is therefore adopted in two clinical trials with either tTCR-T cells redirected against NY-ESO-1 (in MM, melanoma, or subtypes of sarcoma) 133 or CAR-T cells redirected against mesothelin (in any mesothelin-positive solid tumor). 134 PD-1 is also knocked out in the tTCR-T cells and CAR-T cells in these trials. Initial results of the first trial have been published, and they indicated no major adverse events in the three patients that were included. 135 The patients suffered from advanced refractory malignancies, and the response to therapy was variable: one patient did not respond and died, while two patients showed initial disease stabilization, followed by disease progression after 30 or 100 days. Responses to follow-up treatment in these two patients were variable. Interestingly, the authors reported a relatively long half-life of tTCR-T cells at an average of 83.9 days. As other studies reported a half-life of roughly 1 week of non-edited NY-ESO-1 tTCR-T cells, 136 , 137 , 138 the knockout of PD-1 and/or endogenous TCR components might have contributed to a slower decay of the tTCR-T cells.

A Special Case: ACT for T Cell Malignancies

It is particularly challenging to design an effective ACT using T cells for T cell malignancies. T cells should target molecules that are preferably expressed by malignant T cells but not by normal T cells. The difficulty in finding specific targets in malignant T cells results in self-destruction of tTCR-T cells or CAR-T cells cells used in ACT. 139 This process, called fratricide, can interfere with ACT efficacy and has been observed in both CAR-T cells 140 and transgenic TCR-T cells. 141 One possible solution to this problem is to knockout the target molecule in the adoptive T cells by gene editing. In this way, transgenic TCR-T or CAR-T cells will recognize and attack malignant T cells, but not each other. This strategy has been proven effective in circumventing fratricide in a preclinical setting, 142 , 143 and it is currently applied in a clinical trial applied to CD7. CD7 is expressed on the cell surface of T cells, and in this trial anti-CD7 CAR-T cells are tested for the treatment of T cell leukemia/lymphoma. To prevent fratricide, CD7 was knocked out in CAR-T cells using CRISPR-Cas9 ( Figure 2 ). 144 In addition, one previously mentioned clinical trial investigates universal anti-CD7 CAR-T cells in T cell malignancies, but knockout of CD7 in the CAR-T cells has not been mentioned. 124 Figure 2 CD7 Knockout in Anti-CD7 CAR-T Cells Prevents Fratricide (A) Anti-CD7 CAR-T cells recognize the CD7 antigen on (malignant) T cells via their chimeric antigen receptor, which triggers the CAR-T cell cytotoxic function and thus results in lysis of the target cell. CD7 is expressed on the surface of all T cells. As CAR-T cells also express CD7, CAR-T cells will recognize other CAR-T cells and lyse these, which is termed fratricide. (B) The gene encoding CD7 can be knocked out in anti-CD7 CAR-T cells, for example by CRISPR-Cas9. Without CD7, these CAR-T cells will not be recognized and lysed by other anti-CD7 CAR-T cells, thus preventing fratricide. Red indicates the result of intervention.

Gene Editing in Viral Infection

Cervical Cancer

Cervical cancer is the third most prevalent type of cancer in women worldwide. 145 The most contributing etiological factor is human papillomavirus (HPV) infection via sexual intercourse, especially serotypes HPV-16 and HPV-18. Most HPV infections are cleared by the host immune system, but persistent infections can give rise to malignant transformation. Several vaccines have been developed for primary prevention of cervix carcinoma, with varying levels of population coverage worldwide. 146 Premalignant lesions are treated by local excision, while therapeutic modalities for invasive cervix carcinoma are dependent on the cancer stage and include surgery, radiotherapy, and chemotherapy. 147 In spite of these preventive and curative modalities, survival rates of cervical cancer range from 93% at early disease stage to 15% at disseminated disease stage. 148 New treatment modalities are crucial to increase survival rates of cervix carcinoma.

One such recent advance is RNA interference (RNAi)-mediated knockdown of the viral oncogenes E6 and E7, as these have been identified to drive and sustain HPV-related carcinogenesis. 149 In multiple studies, knockdown of E6 and E7 resulted in increased cell death in HPV-positive cell lines. 150 , 151 However, multiple obstacles, such as the occurrence of escape mechanisms and insufficient efficiency, have prohibited RNA-based strategies from entering clinical trials so far. 152 Guided gene knockout might partially overcome these limitations. First of all, RNAi only lowers target gene expression, whereas gene editing can completely disrupt or delete a gene, leaving no room for residual gene expression. Mutation of the target region, a known escape mechanism of RNA viruses, as observed in studies using RNAi-mediated knockdown, likely still applies to knockout strategies using gene editing. Another escape mechanism, which is expression of viral suppressors of RNAi, is expected not to apply to gene editing. 153 Investigating viral escape from strategies involving gene editing in cervical cancer caused by HPV will be an important aspect in future research. As is true for any cancer, it will be important to start treatment at the earliest stage possible and to use treatments that are highly efficient.

Gene editing for treating HPV infection has focused on E6 and E7 . It is generally appealing to target viral genes, because these are exogenous sequences, reducing the chances of unintended off-target events in endogenous genes. Successful knockout of E6 and E7 genes has been achieved via ZFNs, 154 TALENs, 155 , 156 and CRISPR-Cas9. 157 , 158 , 159 The in vitro knockout of viral E6 or E7 sequences in HPV-infected cell line models caused inhibition of cell growth and cell viability, which is in line with results obtained from RNAi. In addition, gene-edited cells showed reduced capability to engraft in mice compared to unedited cells when transplanted subcutaneously. 154 , 155 , 157 Results were consistent for targeting HPV-16 and HPV-18. 155 Furthermore, in vivo gene editing with topically applied TALEN components using polymer-complexed T512 plasmids in K14-HPV16 transgenic mice, a model system for cervical HPV-16 infection, resulted in reduced viral DNA loads and a reversal of histological malignant abnormalities. 155 As only the TALEN platform was topically applied in vivo in a cervical cancer mouse model, 155 the effects of topically applied gene editing tools on cervical cancer could not be compared. Based on these results, multiple clinical trials have been designed to investigate gene editing of precancerous cervical lesions, directed at the HPV genome. These clinical trials apply either ZFN, 160 TALEN, 161 , 162 or CRISPR-Cas9 162 gene editing platforms, which are administered either by topical gel or vaginal suppository.

In the future, topically applied gene editing tools might be investigated in combination with chemotherapy in metastasized cervix carcinoma. Preclinically, an additive anti-cancer effect of gene editing was already shown in vitro and in vivo in combination with cisplatin. 163 In addition, the potential of HPV targeting extends beyond the treatment of cervix carcinoma, as HPV-related cancers include other anogenital cancers such as vulvar, vaginal, anal, and penile cancer, but also cancers in the head and neck region. 164 In preclinical studies, CRISPR-Cas9-based strategies have been tested for treating other chronic viral infections, such as hepatitis B virus, 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 Epstein-Barr virus, 173 , 174 , 175 , 176 and human immunodeficiency virus (HIV) (see section below). As these viral infections affect distinct tissues and/or have distinct modes of action, these might need tailored strategies for delivery to the required target. An overview of these gene editing strategies is provided in a review by de Buhr and Lebbink. 177

Gene Editing in HIV Infection and AIDS

HIV is a lentivirus that integrates its genome (after reverse transcription of its RNA into DNA) into the genome of host CD4 + T helper cells, forming a provirus. After the initial acute phase of infection, a pool of T cells remains latently infected. When the provirus becomes activated, host cells produce new viral particles and undergo cell death. This causes acquired immunodeficiency syndrome (AIDS) if the numbers of T helper cells drop to levels that are insufficient to effectively protect the host from infections or malignant transformations. 178 Currently, HIV infections are treated by antiretroviral therapy (ART) to reduce the risk of progression to AIDS. However, ART needs to be taken life-long, requires adherence to the treatment regimen, and can have side effects and incomplete efficacy. 179 , 180 Although no curative treatment has been found to date, there are two documented cases of HIV patients who have been cured from HIV infection. The first patient, known as the Berlin patient, received two HSC transplantations for AML, and has remained HIV-negative since. 181 , 182 His donor harbored a homozygous CCR5 Δ32/Δ32 loss-of-function allele, which had previously been known to impair infection of T cells by HIV-1. 183 A similar second patient was identified recently. 184 In addition, genetic association studies have shown that CCR5Δ32 homozygotes are resistant to HIV infection, whereas heterozygotes display delayed progression of disease. 185 , 186 , 187 It was therefore hypothesized that ex vivo disruption of CCR5 in patient-derived T cells, followed by reinfusion, could mimic the curative outcome of the Berlin patient. CCR5 was targeted by ZFNs in human primary CD4 + T cells, and biallelic gene disruption was achieved in 33% of modified cells in vitro . 188 In an HIV infection mouse model, injection of CCR5 KO T cells resulted in decreased viral load and an increased T cell population compared to wild-type T cells. 188 Six out of a total of seven clinical trials assessing the infusion of autologous CD4 + CCR5 knockout T cells using ZFNs have been completed, 189 , 190 , 191 , 192 , 193 , 194 , 195 and results of one have been published. 196 In the study of Tebas et al., 196 CD4 + CCR5 KO T cell infusion proved to be safe in HIV patients. In addition, levels of blood HIV DNA decreased in most patients, although the trial was not designed to measure efficacy. One clinical trial is currently investigating the long-term effects of CCR5 -edited T cells. 197

It is unclear how long engineered T cells can in principle protect against AIDS given their limited lifespan. Therefore, several groups are focusing on deleting CCR5 in HSCs, as these have self-renewal capacity to remain present as stem cells and can give rise to all cells of the hematopoietic lineage. 198 HSCs would for example also give rise to CD4 + myeloid cells, which are also susceptible to HIV infection. 199 CCR5 disruption by ZFNs was achieved in human CD34 + HSCs, and these cells were able to engraft in immunosuppressed or immunodeficient mice. 200 , 201 , 202 In addition, infusion of CCR5 -modified HSCs resulted in reduced plasma HIV levels in mouse models when compared to unmodified HSC infusions. 202 Currently, two clinical trials are recruiting patients to test this strategy using either ZFN 203 or CRISPR-Cas9. 204

The previous strategies involve supplying patients with HIV-resistant cells to diminish the effect of HIV on the immune system. Alternatively, CAR-T cells that are redirected toward HIV-related proteins can be applied to actively attack T cells that are infected by the virus. 205 Via gene editing, CCR5 might be disrupted in the CAR-T cells to prevent HIV from infecting these cells. Multiple clinical trials are planned or ongoing for CAR-T cells as a treatment option for HIV. In one of those, ZFNs are applied to disrupt CCR5 in CAR-T cells. 206

CCR5 disruption will not be efficacious in all patients, since CCR5 might be redundant for cell entry by certain HIV strains. 207 , 208 Another disadvantage is the necessity of biallelic knockout of CCR5 to efficiently impair viral reproduction. 198 , 209 An alternative is disruption of the HIV genome itself, which may be especially attractive since this is not an endogenous sequence and may therefore be less susceptible to off-target effects. Targeted disruption of the HIV genome, however, faces the challenge of mutational escape. Another challenge is that HIV-1 forms a stable reservoir in resting CD4 + T cells, which sustains the disease and causes the residual viremia in patients undergoing ART. 210 If the latent reservoir could be directly targeted or activated, HIV infection could possibly be cured without the requirement of myeloablative therapy and subsequent HSC transplantation. Multiple proof-of-principle studies have shown the feasibility of targeting HIV genomic sequences in infected cells in vitro , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 but the problems of mutational escape and targeting the HIV latent reservoir have not been solved to date. 220

Alternatively, the strategies mentioned above could be realized via RNAi. CCR5 knockdown by short hairpin RNA (shRNA) in HSCs or T cells has been readily tested in preclinical studies and is the subject of a phase I/II clinical trial. 221 Targeting of HIV transcripts by RNAi has also been tested preclinically. 221 Besides mutational esacape mentioned above, RNAi faces the additional challenge of transcriptional upregulation of the target in response to knockdown. 222

Exciting preclinical studies have shown the feasibility for applying gene editing to the engineering of B cells that produce antibodies specific to a number of viruses, including Rous sarcoma virus (RSV), influenza virus, Epstein-Barr virus (EBV), or HIV, all of which are viruses for which there is to date no vaccine available. In the example of HIV, broad neutralizing antibodies (bNAbs) have been detected in a small number of infected individuals at ∼1–3 years after infection. 223 These NAbs protect against HIV infection. Primary human B cells have been successfully engineered using CRISPR-Cas9 to produce NAbs against HIV, 224 and a proof of principle using engineered mouse B cells provided protection against infection with RSV. 225

Gene Editing in Hematological Disorders

β-thalassemia and Sickle Cell Disease

β-thalassemia is an autosomal recessive disease with more than 200 known disease-associated variants in the gene coding for the hemoglobin β chain ( HBB ), resulting in a clinically variable phenotype. All of these variants cause reduced or abolished translation of the HBB protein. 226 Approximately 98% of total adult hemoglobin is composed of hemoglobin A (HbA), which is formed by two β-globin subunits bound to two α-globin subunits. 227 Reduced expression of the β-globin subunit results in a relative excess of the α-globin subunit, resulting in precipitation of the α-globin subunit in erythroblasts and erythrocytes. This ultimately leads to impaired erythropoiesis and hemolysis, and thus anemia.

Treatment of β-thalassemia depends on life-long supportive measures, of which blood transfusion is the main component. β-Thalassemia patients either have transfusion-dependent thalassemia (TDT) or non-TDT (NTDT). 228 TDT patients require life-long blood transfusions for survival, starting at an average age of 2 years for every 2–5 weeks, while NTDT patients need blood transfusions only occasionally or for limited periods of time. 228 Regular transfusions place patients at risk of blood-borne infections, iron overload, and transfusion reactions. 229 In addition, 80% of TDT patients develop long-term complications. 230 Although long-term complications due to iron overload result in decreased longevity, a life expectancy of over 50 years of age has been estimated. 231 Recurrent therapy, adverse events, and complications also negatively impact patients quality of life. Furthermore, treatment of β-thalassemia patients with iron chelation therapy is essential to reduce iron overload, but it results in considerable additional costs. In addition, through alloimmunization, it becomes increasingly challenging to find eligible blood products. 229 The only curative therapy to date is allogeneic HSC transplantation, provided that a suitable donor is available. An HLA-matched sibling donor is available in about 30% of cases. 232 For the remaining patients an unrelated HLA-matched donor should be considered, which approaches success rates of sibling donors. However, for 20%–30% of patients needing an HSC transplantation (without considering the underlying disease), no optimal unrelated HLA-matched donor can be found even with the extensive donor registries that have been established in Europe. 233 For 5% of patients, no donor could be identified at all. The alternative of cord blood transplantation from unrelated donors, for which HLA matching is less stringent, is less favorable due to higher rates of graft failure. 234 Haploidentical, or half-matched (e.g., parents or children), stem cell transplantation seems inferior to HLA-matched unrelated transplantation due to delayed restoration of the immune system, although experience is limited. 232 Between 2000 and 2010, the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry reported treatment outcomes for all HSC transplantations, showing a 2-year event-free survival rate of more than 80% in TDT patients. However, this study also revealed a 12% overall mortality within 2 years after allogeneic HSC transplantation and the required (myeloablative) conditioning. In addition, 10% of patients developed severe acute GvHD, and about 15% of patients developed chronic GvHD. 235

In sickle cell disease (SCD), the β-globin subunit in HbA carries a point variant that results in the formation of an aberrant form termed hemoglobin S. The HBB p.Glu6Val variant in combination with the same or a second HBB disease-associated variant on the second allele leads to SCD, in which erythrocytes are malformed, resulting in chronic hemolytic anemia. The malformed erythrocytes can cause acute ischemia throughout the body due to obstruction of blood vessels, leading to (severe) pain, organ failure, and severe acute vaso-occlusive complications such as acute chest syndrome or stroke, 236 which can be treated by exchange transfusion. 237 With this therapy, the patients’ blood is exchanged with donor blood to lower the percentage of sickle cells. Chronic transfusions are performed in patients with a history of stroke to prevent new cerebral ischemic events. 237 Possible complications of frequent transfusions have been described previously. Frequently hospitalized patients, for example due to acute chest syndrome or the need for intravenous analgesics in the management of acute pain, are treated with hydroxyurea. These treatments, hospital admissions, acute complications, and many more chronic complications result in reduced life quality of patients. 237 As in β-thalassemia, allogeneic HSC transplantation is the only cure for SCD. Although HSC transplantation with a product of a related HLA-matched donor seems successful in most cases, severe complications as described previously are also seen in SCD. 238 Recent improvements in conditioning regimens have led to reduced intensity treatment without short-term GvHD, but serious adverse events still occurred. 239 , 240 The experience with other HSC transplantation sources is scarce in SCD, but it seems inferior to related HLA-matched donors. 238 , 241

Curative options that are less toxic than allogeneic HSC transplantation are required for both β-thalassemia and SCD. As gene therapy allows the engineering of autologous stem cells, the need for a donor would be bypassed. Importantly, transfusion of autologous rather than allogeneic stem cells strongly reduces the HSC transplantation-related toxicity. 242 Reports of gene therapy using lentiviral vectors to add a healthy HBB copy to HSCs in vitro for reinfusion purposes have been published for β-thalassemia 243 and SCD, 244 and the first promising (interim) results of clinical trials have been reported. 245 , 246 As the graft must replenish the hematopoietic system through rapid cell division, an integrative vector, such as lentiviral vectors, is required. Although γ-retroviral vectors used in the past gave rise to leukemia through insertional mutagenesis, 247 currently used third-generation self-inactivating lentiviruses have an improved safety profile and have been used without adverse events in several clinical trials up to 7 years follow-up. 248 , 249 , 250 , 251 , 252 , 253 , 254 , 255 Because lentiviral transduction is highly efficient, it provides a strong competitor for gene editing approaches in strategies involving overexpression of transgenes.

The main strategy under current investigation for clinical application of gene editing is the induction of endogenous expression of fetal hemoglobin (HbF). This originated from the observation that co-inheritance of hereditary persistence of HbF (HPFH), a benign condition, reduces symptoms of SCD and β-thalassemia. 227 The situation in SCD and β-thalassemia is depicted in Figure 3 A. In HPFH, HbF protein production continues into adulthood, whereas under normal physiological conditions production shifts to adult hemoglobin after birth. HbF protein contains two subunits of α-globin and γ-globin each, the latter of which are translated from the HBG gene. Persistent HbF expression in HPFH compensates for the reduced production of HbA in β-thalassemia patients. There is a difference in HbF protein levels among β-thalassemia patients, and this has been linked to several genetic variants, with single nucleotide variants (SNVs) in the BCL11A gene correlating most strongly with HbF expression. 256 Reduced BCL11A protein expression is correlated with increased HbF protein expression, likely because BCL11A suppresses HbF expression by binding directly to the HBG promoter. 257 , 258 BCL11A null mice were shown to be unable to downregulate murine embryonic globin in erythrocytes, demonstrating the essential role of BCL11A in repression of HbF expression during development. 259 However, BCL11A knockdown by gene disruption in HSCs results in impaired engraftment of HSC in mice, illustrating that knockout of BCL11A itself is not a feasible strategy to treat β-thalassemia. 260 As BCL11A expression during erythropoiesis is specifically regulated by the intronic erythroid-specific enhancer, 261 disrupting this enhancer will result in BCL11A knockout during erythropoiesis, exclusively. This strategy was preclinically tested by using ZFN-mediated gene disruption of the GATAA element of the BCL11A erythroid-specific enhancer in HSCs ( Figure 3 B). 260 , 262 These cells achieved robust long-term engraftment in mice and gave rise to erythroid cells with elevated HbF levels upon ex vivo culture of chimeric bone marrow. 260 Multiple clinical trials are based on a strategy involving HSCs, of which the intronic erythroid-specific enhancer of BCL11A is disrupted ex vivo using CRISPR-Cas9 or ZFNs as a treatment for TDT 263 , 264 or SCD 265 , 266 patients. The long-term effects of infusing such cells are investigated in one clinical trial. 267 Other strategies to increase HbF expression include disruption of the binding motif for BCL11A (and co-repressive proteins) within the HBG promoter sequence ( Figure 3 C) 257 , 268 , 269 or the induction of a natural occurring variant termed the Sicilian HPFH disease-associated variant ( Figure 3 D). 270 In the latter variant, the entire β-globin locus is deleted and the putative 3′ β-globin enhancer is brought in closer proximity to the γ-globin locus. These strategies have been explored preclinically, but have not (yet) reached clinical application. Figure 3 Gene Editing Strategies in β-Thalassemia and Sickle Cell Disease (A) Situation in β-thalassemia and sickle cell disease. The locus control region (LCR) loops to the β-globin gene and β-globin is expressed; however, due to a disease-associated variant in the β-globin gene there is insufficient expression (β-thalassemia) or malformed (sickle cell disease) β-globin. The transcriptional repressor BCL11A recognizes the first TGACCA binding sequence, which leads to inhibition of expression of fetal-specific γ-globin. (B) In one strategy, CRISPR-Cas9 or ZFNs (not shown) are used for targeted disruption of the GATAA motif in the intronic erythroid-specific enhancer of BCL11A , which will result in disruption of BCL11A expression during erythropoiesis and consequently relief of inhibition of γ-globin expression. γ-Globin will substitute for the lack of β-globin to form functional hemoglobin: HbF. (C) In a related strategy, the TGACCA recognition site for BCL11A is disrupted using CRISPR-Cas9 or ZFNs (not shown). BLC11A remains expressed but cannot bind to the recognition site to inhibit the γ-globin expression, resulting in relief of inhibition of γ-globin expression. (D) In another scenario, the β-globin promotor sequence is disrupted using CRISPR-Cas9, leading to a loss of binding sites for proteins that repress expression of γ-globin and subsequent induction of γ-globin expression. (E) Finally, the disease-associated variant can be precisely corrected using CRISPR-Cas9. While strategies in (B), (C), and (D) will lead to the induction of fetal hemoglobin, the strategy in (E) will lead to production of adult hemoglobin. Red indicates the result of intervention.

Besides induction of HbF, other applications of gene editing techniques to treat β-thalassemia and SCD have been tested mainly in preclinical studies. Cai et al. 271 showed an approach to correct various HBB disease-associated variants by inserting a cDNA sequence of exons 2 and 3 of the HBB gene downstream of HBB exon 1 in vitro using CRISPR-Cas9 in induced pluripotent stem cells (iPSCs). This strategy ensured expression of correct β-globin and prevented expression of the mutated variant in iPSC-derived erythrocytes. Other preclinical studies showed the (HDR-mediated) correction of a specific disease-associated variant in (iPSC-induced) HSCs to restore β-globin and thus HbA expression ( Figure 3 E). 272 , 273 , 274 , 275 , 276 , 277 , 278 , 279 One clinical trial implies to investigate the infusion of autologous, iPSC-induced HSCs with a directly gene-corrected version of the HBB gene in β-thalassemia. 280 However, very limited information is provided for this trial and the exact strategy is not elucidated. Another preclinical strategy involves the in vitro knockout of α-globin 281 to prevent its precipitation. No clinical trial has been reported that investigates this option.

Gene Editing in Hemophilia

Hemophilia A and B are congenital bleeding disorders caused by deficiencies in clotting factor VIII (FVIII) or IX (FIX), respectively. These diseases have a recessive X-linked inheritance pattern. Protein substitution therapy (PST) with recombinant clotting factor or protein derived from donor plasma is currently the main treatment for these patients. 282 Despite the steep increase in life expectancy and the improved prevention of arthropathies due to articular bleedings after introduction of PST, this treatment has its drawbacks. 282 , 283 As substituting a deficient protein is not curative, repeated administration is required and patients remain at risk of bleedings. In addition, costs related to PST are considerable. 282 Insertion of a functional copy of the deficient gene in patient cells could potentially provide a long-term cure for hemophilia. To this end, in vivo gene therapy by viral vectors has been applied in multiple phase I clinical trials, 284 , 285 , 286 as well as by ex vivo electroporation of fibroblasts that provided a source of FVIII after engraftment. 287 Initial results observed in these clinical trials were disappointing. 282 For lentiviral transduction, preclinical optimization of ex vivo HSC-mediated lentiviral gene therapy is paving the way for the first clinical studies. 282 In spite of subclinical effects of targeting muscle cells by AAV vectors in hemophilia, promising clinical results have been obtained by the use of AAV vectors targeting liver cells. 282 Transient liver toxicity and a temporary requirement for immunosuppressive therapy were drawbacks of this strategy.

Currently, gene editing strategies to target liver cells are also being explored for hemophilia. Sharma et al. 288 achieved robust expression of human FVIII or FIX by integrating the cDNA of either gene into intron 1 of the albumin locus in primary hepatocytes in vitro and in hepatocytes of mice in vivo by using AAV-delivered ZFN-mediated gene editing. Despite the low in vivo genome editing efficiency, gene expression was achieved by placing the genes under the control of the highly active albumin promoter. This in vivo gene editing strategy is currently being investigated in hemophilia B patients in a clinical trial. 289 A drawback for clinical implementation of such strategy is the long-term presence of active gene editing components in the liver of patients and the associated risk of damaging the genome by introducing double-stranded breaks at off-target loci. This is a serious concern, as the gene editing machinery delivered by AAV has an expected presence in the liver of several years, which significantly increases the chance for off-target effects to occur. This highlights the need for developing more transient ways to perform in vivo gene editing.

Other preclinical strategies that are under investigation include insertion of the transgene into the AAVS1 locus 290 , 291 or in the native locus 292 , 293 , 294 , 295 and correction of disease-associated variants 296 , 297 , 298 or large chromosomal rearrangements. 299 , 300 , 301

For the clinical translation of gene editing in HSCs, a critical aspect is to maintain long-term engraftment capacity. 201 , 302 , 303 , 304 , 305 Similar to most other cells, HDR-mediated gene editing is challenging in HSCs, as these cells prefer the NHEJ pathway. In addition, it has been found that genetic manipulation of HSCs with gene editing or viral vectors can reduce their engraftment capacity. This has been found to be caused by activation of the DNA damage response pathway, resulting in activation of p53. Transient inhibition of p53 has been found to improve long-term engraftment of HSCs after gene editing. 344 In addition, technical optimizations related to cell culture, delivery, and use of reagents have resulted in enhanced long-term engraftment of HSCs after gene editing in xenograft experiments involving transplantation of human HSCs into immunodeficient mice. The clinical testing of long-term engraftment of gene-edited HSCs in human patients needs further testing.

Gene Editing in Metabolic Disorders

Mucopolysaccharidoses

Mucopolysaccharidoses (MPSs) are monogenic lysosomal storage diseases (LSDs) in which one of the enzymes involved in the lysosomal degradation of glycosaminoglycans (GAGs) is deficient. In MPS I and II, this concerns the α- l -iduronidase (IDUA) and iduronate-2-sulfatase (IDS) enzymes, respectively. Patients suffer from multisystemic symptoms and reduced life expectancy that can vary depending on the type of MPS and the severity of the disease-associated variant. 306 The currently available treatment for MPS I, MPS II, MPS IVA, MPS VI, and MPS VII is enzyme replacement therapy (ERT), in which recombinant enzyme is administered intravenously. Drawbacks of ERT include the non-curative nature of the treatment, the requirement of repeated intravenous infusions, high costs, and ineffectiveness in treating symptoms in bone, cartilage, heart valves, and the central nervous system. 307 , 308 In addition, generation of antibodies against the recombinant enzyme can interfere with the efficacy of ERT. 307 HSC transplantation is currently applied to treat MPS I. 309 This relies on the principle that lysosomal enzymes are secreted and can be taken up by target cells via the cation-independent mannose 6-phosphate receptor (CI-M6PR). In HSC transplantation, HSCs and their progeny secrete the enzyme into the circulation and provide a continuous source of ERT. In the case of MPS I, the level of secretion and reuptake provides partial efficacy in target organs. However, HSC transplantation depends on the availability of HLA-matched donors and can have severe adverse events such as GvHD, infection, and even death, as described before. 306 In addition, the therapeutic effect on the skeletal abnormalities and neurological symptoms is limited, and for many other LSDs, endogenous expression levels in HSCs are insufficient to treat target organs. Therefore, overexpression by ex vivo lentiviral transduction or gene editing provides (additional) therapeutic efficacy. For MPS I, liposome-mediated delivery of CRISPR-Cas9 has been successfully applied in vivo and resulted in increased IDUA expression in newborn MPS I mice. 310 Alternatively, direct gene addition using AAV vectors (without gene editing) has been shown feasible in preclinical studies for several MPS types. 311 , 312 , 313 , 314 , 315 , 316 This strategy is being investigated in multiple clinical trials, and recent results using intracerebral delivery showed promising outcomes with respect to treating the neurological decline of MPS IIIB patients. 317

Another approach, similar to the approach in hemophilia, is the site-specific integration of a transgene in the liver by in vivo genome editing following intravenous administration using AAV as the delivery method. 288 Most efforts have been made on integrating transgenes into the albumin locus. Sharma et al. 288 achieved ZFN-mediated insertion of IDUA and IDS in vivo into the albumin locus of healthy mice, resulting in detectable protein levels in liver lysates. More recently, ZFN-mediated insertion of human IDS in the albumin locus in murine liver in vivo was accompanied by a dose-dependent rise in circulating enzyme levels. 318 This IDS insertion caused reduction of GAG levels in tissue and urine samples of MPS II mice. These results have led to clinical trials investigating the safety of ascending dose levels of AAV vectors containing components required for in vivo ZFN-mediated insertion of IDUA and IDS genes into the albumin locus of hepatocytes in the liver of MPS I patients 319 and MPS II patients, 320 respectively. The same drawbacks as in the hemophilia trial with respect to safety due to the potential introduction of double-stranded breaks in the liver at off-target locations in the genome apply here due to the long-term exposure of the patient to the uncontrolled activity of ZNF-mediated double-stranded breaks.

Gene Editing in the Eye

Leber’s Congenital Amaurosis

Leber’s congenital amaurosis (LCA) is an inherited retinopathy in which severe visual impairment or blindness occurs within the first months of life. 321 It is a genetically heterogeneous disease that can be caused by any of more than 20 mutated genes. Based on the genes involved and the ocular phenotypes, LCA is divided into 13 subtypes. 322 Currently, there is no treatment for LCA. In clinical trials, it has already been shown that AAV-mediated gene transfer by subretinal injection resulted in improved visual parameters in patients with the LCA type LCA2, which is caused by variants in the RPE6 gene. 323 , 324 , 325 , 326 Retinal dystrophy in LCA was (at least partially) reversed by the therapy. AAV-mediated gene therapy has also been applied to other congenital retinopathies. 327

In addition to AAV-mediated gene transfer, gene editing is in development for retinopathies. For subtype LCA10, which is caused by variants in the CEP290 gene, 321 , 328 a clinical trial is currently open 329 with the strategy outline below. Gene transfer via viral vectors (especially AAV) is problematic for CEP290 due to the large gene size. CEP290 encodes a protein that is essential for cilia, which are microtubule-based, hair-like extensions of cell membranes. 330 In photoreceptor cells, cilia are highly specialized into cone- or rod-shaped segments that act as light sensors and signal transducers. 322 In LCA10, CEP920 disease-associated variants cause (peripheral) thickening of the retina by an unknown mechanism. 330 The most common variant is the intronic variant IVS26, which results in the generation of a cryptic splice site that causes an abrogated protein product. 328 Preclinical studies had shown that, using subretinal injections of AAV5 vectors containing the CRISPR-Cas9 gene editing machinery, it deletion of the cryptic splice site leads to restoration of canonical splicing and expression of wild-type protein. 331 , 332 This concept is used in the ongoing clinical trial. 329 Other preclinical studies are investigating gene editing strategies for other disease-associated variants in LCA and other retinopathies. 333 , 334 However, long-term expression of CRISPR-Cas9 in the eye imposes safety risks, as discussed in approaches for in vivo gene editing in hemophilia and MPS I and II.

Conclusions and Future Prospects

Disease-Specific Challenges

The challenges and opportunities of applying gene editing for the treatment of human disease depend in part on disease-specific aspects. In cancer immunotherapy, a major challenge is to specifically target cancer cells while leaving healthy cells unharmed. Targeting immune checkpoints with gene editing has been shown to be a promising strategy, but the clinical feasibility relies in part on the inherent problem of specificity: by inhibiting a general checkpoint with the aim to inhibit negative immune regulation, there is a risk of auto-immune-related side effects. Considering the life-threatening nature of cancer, this disadvantage may be acceptable if survival rates can be improved and increased toxicity is manageable. Other challenges include the viability of T cells that have been gene edited ex vivo to knock out immune checkpoint regulators. These cells do not need to be present life-long, but they should have sufficient viability in order to help eliminating cancer cells. If needed, repeated administration would be an option, but this will increase costs. The development of a universal ACT would be an elegant solution to the high costs of preparing autologous or HLA-matched allogeneic gene-edited T cells for each individual patient, although this approach has the risk of inducing GvHD.

Application of targeted knockout to viral infection such as HPV could provide a useful additional treatment option when it comes to treating the primary tumor. However, a high effciency of gene knockout is reqired to effectively reduce the tumor, and treating metastases is not yet possible due to the difficulty to reach target tissues and to eliminate the HPV virus in a safe and efficient manner outside the primary tumor. It might be an advantage to target viral sequences rather than endogenous genomic locations to reduce the risks of undesired genomic alterations as the result of gene editing. This could also be a potential advantage for strategies that eradicate HIV provirus from the genome. In the case of HIV, disease-specific challenges include the targeting of the dormant HIV reservoir, and to target HIV strains that do not depend on CCR5 for infection.

Ex Vivo Gene Editing

In both genetic disease and viral infection, promising strategies using ex vivo gene editing lie ahead for disorders that can be cured via the blood, including hematological disorders, lysosomal storage disorders, and HIV infection. The main reason for this is the feasibility to target blood cells such as HSCs or T cells ex vivo and to engraft autologous gene-modified cells back into patients. This approach relies on the long-standing experience with successful engraftment of HSCs, which has nowadays become a standard procedure with a very good safety profile. In addition, engrafted HSCs can provide a life-long treatment because they can self-renew to sustain the stem cell population and to differentiate into the hematopoietic lineage. Because prolonged ex vivo culture reduces engraftment potential and stem cell properties of HSCs, fast and efficient methods are required to make ex vivo gene editing of HSCs feasible for clinical implementation. It remains to be seen whether ex vivo gene editing for overexpressing proteins will be able to successfully compete with ex vivo lentiviral transduction of HSCs when it comes to clinical implementation, because lentiviral transduction is highly efficient, has been used more than 7 years without adverse events in several clinical trials, and could be more cost-effective. 248 , 249 , 250 , 251 , 252 , 253 , 254 , 255 Strategies that rely on NHEJ are inherently more efficient compared to the HDR-mediated insertion of transgenes, and these provide promising options for the treatment of HIV infection, by knocking out the CCR5 receptor, or some genetic disorders such as β-thalassemia and SCD, by knocking out regulatory elements required for BCL11A-mediated negative regulation of HbF expression.

Among the many other preclinical developments for using ex vivo gene-edited HSCs (not covered in this review), the primary immunodeficiency diseases (PIDs) represent a promising example. 335 , 336 These patients usually benefit from allogeneic HSC transplantation from HLA-matched donors, but these are not always available, and allogeneic HSCs can induce GvHD. Autologous HSC transplantation following ex vivo gene therapy employing third-generation lentiviruses is ongoing in a number of clinical trials for Wiskott-Aldrich syndrome, ADA severe combined immunodeficiency (ADA-SCID), X-linked SCID, and chronic granulomatous disease (CGD). However, many PIDs involve genes with a timed and restricted expression pattern during development and require endogenous expression levels via the natural promoter rather than overexpression. Gene editing would be advantageous above lentiviral transduction in these cases, as it enables precise correction of an endogenous allele to maintain endogenous expression levels. There are currently no clinical trials for PIDs reported using gene editing, but promising preclinical developments may change this in the near future.

Other promising preclinical developments include the ex vivo gene editing of primary hepatocytes for metabolic disease of the liver. As a proof of concept, AAV-mediated delivery of CRISPR-Cas9 to freshly isolated mouse hepatocytes was used, followed by engraftment into the liver of a mouse model. This concept was applied to treat hereditary tyrosinemia in a mouse model to correct a point variant in the fumarylacetoacetate hydrolase gene using HDR. 337 A major challenge for this approach is the limited engraftment capacity of hepatocytes in human liver. In cystic fibrosis, investigators are pursuing gene editing of stem cells derived from the airways with the ultimate goal of developing a gene-edited autologous airway stem cell transplantation. 338 Mitochondrial diseases that are caused by disease-associated variants in mitochondrial DNA form an attractive target for gene editing. 339 , 340 However, gene editing of mitochondrial DNA is even more challenging than nuclear DNA, and improvements are required before clinical applications can be considered in the near future.

In all of these possible applications, the ex vivo mode of gene editing ensures that a quality control can be performed prior to decision-making of engrafting cells into patients. Reliable methods to assess undesired genomic alterations are essential, and a shift from methods that rely on predictions toward unbiased methods will be required. Quality control should also include functional analysis of cellular transformation, because rare events that result in formation of tumorigenic cells will be very difficult to detect in population-based assays.

In Vivo Gene Editing

In vivo gene editing trials have already started for a number of disorders including lysosomal storage disorders, hemophilia, precancerous cervical lesions and LCA. This is despite the uncertainties of gene editing technology with respect to possible off-target effects. This is particularly important when gene editing technology is introduced in patients without ways for spatiotemporal control (i.e., means to confine gene editing to a short time and specific target tissue, for example by using suicide genes in DNA combined with tissue-specific delivery, or local administration of gene editing tools as RNA/protein rather than DNA), such as is the case in trials so far. This means that gene editing may continue for years inside the patient, which will increase the risk of undesired events with several orders of magnitude compared to ex vivo gene editing. For safe future clinical development, it will be important to develop ways that can control the activity of in vivo gene editing by including on and off switches to prevent the prolonged generation of DNA breaks or by providing the gene editing machinery in other ways than as DNA. In addition, targeting gene editing tools specifically to the cells of interest will further increase the safety by preventing unnecessary targeting events in irrelevant cell types.

These aspects will also guide ongoing preclinical efforts to develop treatments for human disease based on in vivo gene editing. Multiple preclinical developments in different fields are ongoing, and it is beyond the scope of this review to cover these. As examples we mention metabolic disorders that are amenable to correction via knockout of a gene in the metabolic pathway to enable redirecting of metabolism. For example, severe hereditary tyrosinemia type I was successfully redirected to a more begin tyrosinemia type III form by deletion of the upstream metabolic enzyme hydroxyphenylpyruvate dioxygenase in the liver. The method applied involved intravenous injection of DNA encoding Cas9 and sgRNAs in the mouse, which transfected the liver more efficiently compared to other organs. 341 The same gene was also targeted in as study on in utero correction of hereditary tyrosinemia type I using injection of an adenovirus expressing a base editor and sgRNA into mouse fetuses via the vitelline vein. In the same study, in utero knockout of PCSK9 was achieved with the aim to lower cholesterol levels and the risk of coronary heart disease in wild-type mice.

Precise correction of a point variant in vivo has been demonstrated for example in a mouse model for phenylketonuria (PKU) using base editors that were delivered by intravenous injection and that were expressed via a liver-specific promoter. 342 Gene editing is even applied in preclinical research to increase the fitness of pig organs for future xenotransplantation into humans. By knockout of genes that activate an immune response and retroviral elements, the aims are to generate organs with reduced hazard of graft rejection and xenozoonosis (an infectious disease transmitted from animal to human), respectively. 343 The ultimate goal of these efforts is to overcome the shortage of human organs such as kidneys, hearts, livers, and lungs for transplantation.

Keeping Up with Technological Developments

Finally, it will be important to educate the various stakeholders, including clinicians, patients, and regulatory institutions. The technology for gene editing is moving so fast that it is difficult to cope with all of the developments and their potential benefits and risks. Clinicians need to be educated in order to allow them to judge the feasibility of a clinical trial and whether they are willing to expose their patients to the novel treatment. Patients rely largely on the information that is provided by their treating physician. The prospect of a “cure” via gene repair may be tempting for a patient, and therefore providing balanced and fair information by the physician on the possible benefits and risks provides an essential ingredient for decision-making. The same arguments apply to regulatory institutions, as these will approve or decline clinical protocols and finally market authorization. While the scientific developments in the field of gene editing are continuing with dazzling speed, it will be important to provide education in the field and to closely monitor and regulate clinical developments.

In this review, we compiled all current clinical applications of gene editing and explained the rationale for the underlying strategies. In addition, we summarized preclinical studies that preceded clinical trials and provided examples of preclinical work that might be translated in a clinical setting in the future. As most other reviews focus on specific areas involving gene editing applications, we envision that centralized information on gene therapies will increase awareness of clinicians and researchers in the field of gene therapy outside their specific field of interest, and that this might catalyze new developments. We propose that clinical applications of gene editing in general will be documented in an accessible and transparent manner. We hope that this review precedes the discussion of a central database that includes relevant information of the clinical studies applying gene editing, as well as the underlying considerations with respect to the mechanism of action, safety, and expected results. Ideally, this information should be contributed by investigators involved in these clinical trials, peer-reviewed by experts in the field, and made publicly available prior to the start of such trials. Preferably, an analysis of risks and benefits of gene editing for a specific disease in the context of current treatments should be included, contributing to discussions on technical and ethical aspects of the applications. Such efforts should contribute to increasing transparency and help to inform stakeholders that are involved in clinical trials involving gene editing.

Author Contributions

M.P.T.E., P.H.-H., M.B., and W.W.W.P.P. conceptualized this review, performed literature studies, and wrote the manuscript. All authors interpreted the contents and approved the final manuscript.

Conflicts of Interest

A.T.v.d.P. has provided consulting services for various industries in the field of Pompe disease under an agreement between these industries and Erasmus MC, Rotterdam, the Netherlands. The remaining authors declare no competing interests.

References

1 Colella P. Ronzitti G. Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy Mol. Ther. Methods Clin. Dev. 8 2017 87 104 29326962 10.1016/j.omtm.2017.11.007 PMC5758940

2 Naldini L. Gene therapy returns to centre stage Nature 526 2015 351 360 26469046 10.1038/nature15818

3 Shirley J.L. de Jong Y.P. Terhorst C. Herzog R.W. Immune responses to viral gene therapy vectors Mol. Ther. 28 2020 709 722 31968213 10.1016/j.ymthe.2020.01.001 PMC7054714

4 Rainov N.G. Ren H. Clinical trials with retrovirus mediated gene therapy—what have we learned? J. Neurooncol. 65 2003 227 236 14682373 10.1023/b:neon.0000003652.71665.f2

5 Ronzitti G. Gross D.A. Mingozzi F. Human immune responses to adeno-associated virus (AAV) vectors Front. Immunol. 11 2020 670 32362898 10.3389/fimmu.2020.00670 PMC7181373

6 Gaj T. Gersbach C.A. Barbas C.F. 3rd ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering Trends Biotechnol. 31 2013 397 405 23664777 10.1016/j.tibtech.2013.04.004 PMC3694601

7 Broeders M. Herrero-Hernandez P. Ernst M.P.T. van der Ploeg A.T. Pijnappel W.W.M.P. Sharpening the molecular scissors: advances in gene-editing technology iScience 23 2020 100789 31901636 10.1016/j.isci.2019.100789 PMC6941877

8 Komor A.C. Kim Y.B. Packer M.S. Zuris J.A. Liu D.R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage Nature 533 2016 420 424 27096365 10.1038/nature17946 PMC4873371

9 Gaudelli N.M. Komor A.C. Rees H.A. Packer M.S. Badran A.H. Bryson D.I. Liu D.R. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage Nature 551 2017 464 471 29160308 10.1038/nature24644 PMC5726555

10 Sadelain M. Papapetrou E.P. Bushman F.D. Safe harbours for the integration of new DNA in the human genome Nat. Rev. Cancer 12 2011 51 58 22129804 10.1038/nrc3179

11 van der Wal E. Herrero-Hernandez P. Wan R. Broeders M. In ’t Groen S.L.M. van Gestel T.J.M. van IJcken W.F.J. Cheung T.H. van der Ploeg A.T. Schaaf G.J. Pijnappel W.W.M.P. Large-scale expansion of human iPSC-derived skeletal muscle cells for disease modeling and cell-based therapeutic strategies Stem Cell Reports 10 2018 1975 1990 29731431 10.1016/j.stemcr.2018.04.002 PMC5993675

12 Hsu P.D. Scott D.A. Weinstein J.A. Ran F.A. Konermann S. Agarwala V. Li Y. Fine E.J. Wu X. Shalem O. DNA targeting specificity of RNA-guided Cas9 nucleases Nat. Biotechnol. 31 2013 827 832 23873081 10.1038/nbt.2647 PMC3969858

13 Kosicki M. Tomberg K. Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements Nat. Biotechnol. 36 2018 765 771 30010673 10.1038/nbt.4192 PMC6390938

14 Cornu T.I. Mussolino C. Cathomen T. Refining strategies to translate genome editing to the clinic Nat. Med. 23 2017 415 423 28388605 10.1038/nm.4313

15 Kim D. Luk K. Wolfe S.A. Kim J.S. Evaluating and enhancing target specificity of gene-editing nucleases and deaminases Annu. Rev. Biochem. 88 2019 191 220 30883196 10.1146/annurev-biochem-013118-111730

16 Manghwar H. Li B. Ding X. Hussain A. Lindsey K. Zhang X. Jin S. CRISPR/Cas systems in genome editing: methodologies and tools for sgRNA design, off-target evaluation, and strategies to mitigate off-target effects Adv. Sci. (Weinh.) 7 2020 1902312 32195078 10.1002/advs.201902312 PMC7080517

17 Pattanayak V. Guilinger J.P. Liu D.R. Determining the specificities of TALENs, Cas9, and other genome-editing enzymes Methods Enzymol. 546 2014 47 78 25398335 10.1016/B978-0-12-801185-0.00003-9 PMC4440668

18 Yin H. Kauffman K.J. Anderson D.G. Delivery technologies for genome editing Nat. Rev. Drug Discov. 16 2017 387 399 28337020 10.1038/nrd.2016.280

19 Lino C.A. Harper J.C. Carney J.P. Timlin J.A. Delivering CRISPR: a review of the challenges and approaches Drug Deliv. 25 2018 1234 1257 29801422 10.1080/10717544.2018.1474964 PMC6058482

20 Tong S. Moyo B. Lee C.M. Leong K. Bao G. Engineered materials for in vivo delivery of genome-editing machinery Nat. Rev. Mater. 4 2019 726 737 10.1038/s41578-019-0145-9 PMC8174554 34094589

21 Li A. Tanner M.R. Lee C.M. Hurley A.E. De Giorgi M. Jarrett K.E. Davis T.H. Doerfler A.M. Bao G. Beeton C. Lagor W.R. AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9 Mol. Ther. 28 2020 1432 1441 32348718 10.1016/j.ymthe.2020.04.017 PMC7264438

22 Charlesworth C.T. Deshpande P.S. Dever D.P. Camarena J. Lemgart V.T. Cromer M.K. Vakulskas C.A. Collingwood M.A. Zhang L. Bode N.M. Identification of preexisting adaptive immunity to Cas9 proteins in humans Nat. Med. 25 2019 249 254 30692695 10.1038/s41591-018-0326-x PMC7199589

23 Crudele J.M. Chamberlain J.S. Cas9 immunity creates challenges for CRISPR gene editing therapies Nat. Commun. 9 2018 3497 30158648 10.1038/s41467-018-05843-9 PMC6115392

24 Pickar-Oliver A. Gersbach C.A. The next generation of CRISPR-Cas technologies and applications Nat. Rev. Mol. Cell Biol. 20 2019 490 507 31147612 10.1038/s41580-019-0131-5 PMC7079207

25 Moon S.B. Kim D.Y. Ko J.H. Kim Y.S. Recent advances in the CRISPR genome editing tool set Exp. Mol. Med. 51 2019 1 11 10.1038/s12276-019-0339-7 PMC6828703 31685795

26 Carroll D. Genome editing: past, present, and future Yale J. Biol. Med. 90 2017 653 659 29259529 PMC5733845

27 Suzuki K. Izpisua Belmonte J.C. In vivo genome editing via the HITI method as a tool for gene therapy J. Hum. Genet. 63 2018 157 164 29215090 10.1038/s10038-017-0352-4

28 Chang H.H.Y. Pannunzio N.R. Adachi N. Lieber M.R. Non-homologous DNA end joining and alternative pathways to double-strand break repair Nat. Rev. Mol. Cell Biol. 18 2017 495 506 28512351 10.1038/nrm.2017.48 PMC7062608

29 Molla K.A. Yang Y. CRISPR/Cas-mediated base editing: technical considerations and practical applications Trends Biotechnol. 37 2019 1121 1142 30995964 10.1016/j.tibtech.2019.03.008

30 Anzalone A.V. Randolph P.B. Davis J.R. Sousa A.A. Koblan L.W. Levy J.M. Chen P.J. Wilson C. Newby G.A. Raguram A. Liu D.R. Search-and-replace genome editing without double-strand breaks or donor DNA Nature 576 2019 149 157 31634902 10.1038/s41586-019-1711-4 PMC6907074

31 Tsai S.Q. Wyvekens N. Khayter C. Foden J.A. Thapar V. Reyon D. Goodwin M.J. Aryee M.J. Joung J.K. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing Nat. Biotechnol. 32 2014 569 576 24770325 10.1038/nbt.2908 PMC4090141

32 Kleinstiver B.P. Pattanayak V. Prew M.S. Tsai S.Q. Nguyen N.T. Zheng Z. Joung J.K. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects Nature 529 2016 490 495 26735016 10.1038/nature16526 PMC4851738

33 Slaymaker I.M. Gao L. Zetsche B. Scott D.A. Yan W.X. Zhang F. Rationally engineered Cas9 nucleases with improved specificity Science 351 2016 84 88 26628643 10.1126/science.aad5227 PMC4714946

34 Casini A. Olivieri M. Petris G. Montagna C. Reginato G. Maule G. Lorenzin F. Prandi D. Romanel A. Demichelis F. A highly specific SpCas9 variant is identified by in vivo screening in yeast Nat. Biotechnol. 36 2018 265 271 29431739 10.1038/nbt.4066 PMC6066108

35 Chen J.S. Dagdas Y.S. Kleinstiver B.P. Welch M.M. Sousa A.A. Harrington L.B. Sternberg S.H. Joung J.K. Yildiz A. Doudna J.A. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy Nature 550 2017 407 410 28931002 10.1038/nature24268 PMC5918688

36 Kleinstiver B.P. Prew M.S. Tsai S.Q. Topkar V.V. Nguyen N.T. Zheng Z. Gonzales A.P.W. Li Z. Peterson R.T. Yeh J.R.J. Engineered CRISPR-Cas9 nucleases with altered PAM specificities Nature 523 2015 481 485 26098369 10.1038/nature14592 PMC4540238

37 Fu Y. Sander J.D. Reyon D. Cascio V.M. Joung J.K. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs Nat. Biotechnol. 32 2014 279 284 24463574 10.1038/nbt.2808 PMC3988262

38 Kocak D.D. Josephs E.A. Bhandarkar V. Adkar S.S. Kwon J.B. Gersbach C.A. Increasing the specificity of CRISPR systems with engineered RNA secondary structures Nat. Biotechnol. 37 2019 657 666 30988504 10.1038/s41587-019-0095-1 PMC6626619

39 Yin H. Song C.Q. Suresh S. Kwan S.Y. Wu Q. Walsh S. Ding J. Bogorad R.L. Zhu L.J. Wolfe S.A. Partial DNA-guided Cas9 enables genome editing with reduced off-target activity Nat. Chem. Biol. 14 2018 311 316 29377001 10.1038/nchembio.2559 PMC5902734

40 Lee J. Bayarsaikhan D. Bayarsaikhan G. Kim J.S. Schwarzbach E. Lee B. Recent advances in genome editing of stem cells for drug discovery and therapeutic application Pharmacol. Ther. 209 2020 107501 32061705 10.1016/j.pharmthera.2020.107501

41 You L. Tong R. Li M. Liu Y. Xue J. Lu Y. Advancements and obstacles of CRISPR-Cas9 technology in translational research Mol. Ther. Methods Clin. Dev. 13 2019 359 370 30989086 10.1016/j.omtm.2019.02.008 PMC6447755

42 Coller B.S. Ethics of human genome editing Annu. Rev. Med. 70 2019 289 305 30691366 10.1146/annurev-med-112717-094629 PMC11299715

43 Lea R.A. Niakan K.K. Human germline genome editing Nat. Cell Biol. 21 2019 1479 1489 31792374 10.1038/s41556-019-0424-0

44 Ormond K.E. Mortlock D.P. Scholes D.T. Bombard Y. Brody L.C. Faucett W.A. Garrison N.A. Hercher L. Isasi R. Middleton A. Human germline genome editing Am. J. Hum. Genet. 101 2017 167 176 28777929 10.1016/j.ajhg.2017.06.012 PMC5544380

45 Sukari A. Abdallah N. Nagasaka M. Unleash the power of the mighty T cells-basis of adoptive cellular therapy Crit. Rev. Oncol. Hematol. 136 2019 1 12 30878123 10.1016/j.critrevonc.2019.01.015

46 Yee C. Lizee G. Schueneman A.J. Endogenous T-cell therapy: clinical experience Cancer J. 21 2015 492 500 26588682 10.1097/PPO.0000000000000158

47 Hanahan D. Weinberg R.A. Hallmarks of cancer: the next generation Cell 144 2011 646 674 21376230 10.1016/j.cell.2011.02.013

48 Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy Nat. Rev. Cancer 12 2012 252 264 22437870 10.1038/nrc3239 PMC4856023

49 Hargadon K.M. Johnson C.E. Williams C.J. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors Int. Immunopharmacol. 62 2018 29 39 29990692 10.1016/j.intimp.2018.06.001

50 Topalian S.L. Hodi F.S. Brahmer J.R. Gettinger S.N. Smith D.C. McDermott D.F. Powderly J.D. Carvajal R.D. Sosman J.A. Atkins M.B. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med. 366 2012 2443 2454 22658127 10.1056/NEJMoa1200690 PMC3544539

51 Brahmer J.R. Tykodi S.S. Chow L.Q. Hwu W.J. Topalian S.L. Hwu P. Drake C.G. Camacho L.H. Kauh J. Odunsi K. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med. 366 2012 2455 2465 22658128 10.1056/NEJMoa1200694 PMC3563263

52 Hamid O. Robert C. Daud A. Hodi F.S. Hwu W.J. Kefford R. Wolchok J.D. Hersey P. Joseph R.W. Weber J.S. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N. Engl. J. Med. 369 2013 134 144 23724846 10.1056/NEJMoa1305133 PMC4126516

53 Michot J.M. Bigenwald C. Champiat S. Collins M. Carbonnel F. Postel-Vinay S. Berdelou A. Varga A. Bahleda R. Hollebecque A. Immune-related adverse events with immune checkpoint blockade: a comprehensive review Eur. J. Cancer 54 2016 139 148 26765102 10.1016/j.ejca.2015.11.016

54 Ho W.Y. Nguyen H.N. Wolfl M. Kuball J. Greenberg P.D. In vitro methods for generating CD8 + T-cell clones for immunotherapy from the naïve repertoire J. Immunol. Methods 310 2006 40 52 16469329 10.1016/j.jim.2005.11.023

55 Beane J.D. Lee G. Zheng Z. Mendel M. Abate-Daga D. Bharathan M. Black M. Gandhi N. Yu Z. Chandran S. Clinical scale zinc finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma Mol. Ther. 23 2015 1380 1390 25939491 10.1038/mt.2015.71 PMC4817870

56 Su S. Hu B. Shao J. Shen B. Du J. Du Y. Zhou J. Yu L. Zhang L. Chen F. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients Sci. Rep. 6 2016 20070 26818188 10.1038/srep20070 PMC4730182

57 Marotte L. Simon S. Vignard V. Dupre E. Gantier M. Cruard J. Alberge J.B. Hussong M. Deleine C. Heslan J.M. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes J. Immunother. Cancer 8 2020 e000311 32001504 10.1136/jitc-2019-000311 PMC7057432

58 Menger L. Sledzinska A. Bergerhoff K. Vargas F.A. Smith J. Poirot L. Pule M. Hererro J. Peggs K.S. Quezada S.A. TALEN-mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T-cell persistence and rejection of established tumors Cancer Res. 76 2016 2087 2093 27197251 10.1158/0008-5472.CAN-15-3352

59 Zhao Z. Shi L. Zhang W. Han J. Zhang S. Fu Z. Cai J. CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes Oncotarget 9 2017 5208 5215 29435173 10.18632/oncotarget.23730 PMC5797044

60 Lu S. Yang N. He J. Gong W. Lai Z. Xie L. Tao L. Xu C. Wang H. Zhang G. Generation of cancer-specific cytotoxic PD-1 − T cells using liposome-encapsulated CRISPR/Cas system with dendritic/tumor fusion cells J. Biomed. Nanotechnol. 15 2019 593 601 31165703 10.1166/jbn.2019.2712

61 Wu, S.; Hangzhou Cancer Hospital, Ltd.; Anhui Kedgene Biotechnology Co., Ltd. (2017). PD-1 knockout engineered T cells for advanced esophageal cancer. https://clinicaltrials.gov/ct2/show/NCT03081715 .

62 Lu, Y.; Sichuan University; Chengdu MedGenCell, Co., Ltd. (2016). PD-1 knockout engineered T cells for metastatic non-small cell lung cancer. https://clinicaltrials.gov/ct2/show/NCT02793856 .

63 Chen, S.; Guangzhou Anjie Biomedical Technology Co., Ltd.; University of Technology, Sydney (2018). Therapeutic vaccine plus PD-1 knockout in prostate cancer treatment. https://clinicaltrials.gov/ct2/show/NCT03525652 .

64 Yang, Y.; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2017). PD-1 knockout EBV-CTLs for advanced stage Epstein-Barr virus (EBV) associated malignancies. https://clinicaltrials.gov/ct2/show/NCT03044743 .

65 Lu Y. Xue J. Deng T. Zhou X. Yu K. Deng L. Huang M. Yi X. Liang M. Wang Y. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer Nat. Med. 26 2020 732 740 32341578 10.1038/s41591-020-0840-5

66 Rothlin C.V. Ghosh S. Lifting the innate immune barriers to antitumor immunity J. Immunother. Cancer 8 2020 e000695 32273348 10.1136/jitc-2020-000695 PMC7254113

67 Chiossone L. Dumas P.Y. Vienne M. Vivier E. Natural killer cells and other innate lymphoid cells in cancer Nat. Rev. Immunol. 18 2018 671 688 30209347 10.1038/s41577-018-0061-z

68 Rautela J. Surgenor E. Huntington N.D. Efficient genome editing of human natural killer cells by CRISPR RNP bioRxiv 2018 10.1101/406934 33463756

69 Pomeroy E.J. Hunzeker J.T. Kluesner M.G. Lahr W.S. Smeester B.A. Crosby M.R. Lonetree C.L. Yamamoto K. Bendzick L. Miller J.S. A genetically engineered primary human natural killer cell platform for cancer immunotherapy Mol. Ther. 28 2020 52 63 31704085 10.1016/j.ymthe.2019.10.009 PMC6953961

70 Ruella M. Kalos M. Adoptive immunotherapy for cancer Immunol. Rev. 257 2014 14 38 24329787 10.1111/imr.12136

71 Liu X. Zhao Y. CRISPR/Cas9 genome editing: fueling the revolution in cancer immunotherapy Curr. Res. Transl. Med. 66 2018 39 42 29691200 10.1016/j.retram.2018.04.003

72 Kershaw M.H. Westwood J.A. Darcy P.K. Gene-engineered T cells for cancer therapy Nat. Rev. Cancer 13 2013 525 541 23880905 10.1038/nrc3565

73 Cartellieri M. Bachmann M. Feldmann A. Bippes C. Stamova S. Wehner R. Temme A. Schmitz M. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer J. Biomed. Biotechnol. 2010 2010 956304 20467460 10.1155/2010/956304 PMC2864912

74 Ouchi Y. Patil A. Tamura Y. Nishimasu H. Negishi A. Paul S.K. Takemura N. Satoh T. Kimura Y. Kurachi M. Generation of tumor antigen-specific murine CD8 + T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing Int. Immunol. 30 2018 141 154 29617862 10.1093/intimm/dxy006

75 Guo X. Jiang H. Shi B. Zhou M. Zhang H. Shi Z. Du G. Luo H. Wu X. Wang Y. Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma Front. Pharmacol. 9 2018 1118 30327605 10.3389/fphar.2018.01118 PMC6174208

76 Hu B. Zou Y. Zhang L. Tang J. Niedermann G. Firat E. Huang X. Zhu X. Nucleofection with plasmid DNA for CRISPR/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells Hum. Gene Ther. 30 2019 446 458 29706119 10.1089/hum.2017.234

77 Hu W. Zi Z. Jin Y. Li G. Shao K. Cai Q. Ma X. Wei F. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions Cancer Immunol. Immunother. 68 2019 365 377 30523370 10.1007/s00262-018-2281-2 PMC11028344

78 Rupp L.J. Schumann K. Roybal K.T. Gate R.E. Ye C.J. Lim W.A. Marson A. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells Sci. Rep. 7 2017 737 28389661 10.1038/s41598-017-00462-8 PMC5428439

79 Zhu H. You Y. Shen Z. Shi L. EGFRvIII-CAR-T cells with PD-1 knockout have improved anti-glioma activity Pathol. Oncol. Res. 2020 10.1007/s12253-019-00759-1 Published online January 27, 2020 31989402

80 Maude S.L. Hucks G.E. Seif A.E. Talekar M.K. Teachey D.T. Baniewicz D. Callahan C. Gonzalez V. Nazimuddin F. Gupta M. The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL) J. Clin. Oncol. 35 Suppl 2017 103

81 Chong E.A. Melenhorst J.J. Lacey S.F. Ambrose D.E. Gonzalez V. Levine B.L. June C.H. Schuster S.J. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR Blood 129 2017 1039 1041 28031179 10.1182/blood-2016-09-738245 PMC5391777

82 Shang, X.; Third Military Medical University (2017). CD19 CAR and PD-1 knockout engineered T cells for CD19 positive malignant B-cell derived leukemia and lymphoma. https://clinicaltrials.gov/ct2/show/NCT03298828 .

83 Weidong, H.; Chinese PLA General Hospital (2018). Study of PD-1 gene-knocked out mesothelin-directed CAR-T cells with the conditioning of PC in mesothelin positive multiple solid tumors. https://clinicaltrials.gov/ct2/show/NCT03747965 .

84 Chen, S.; Guangzhou Anjie Biomedical Technology Co., Ltd. (2018). CAR T and PD-1 knockout engineered T cells for esophageal cancer. https://clinicaltrials.gov/ct2/show/NCT03706326 .

85 Chen, S.; Guangzhou Anjie Biomedical Technology Co., Ltd.; University of Technology, Sydney (2018). Anti-MUC1 CAR T cells and PD-1 knockout engineered T cells for NSCLC. https://clinicaltrials.gov/ct2/show/NCT03525782 .

86 Guangxun, G.; Xi’An Yufan Biotechnology Co., Ltd. (2019). CRISPR (HPK1) edited CD19-specific CAR-T cells (XYF19 CAR-T cells) for CD19 + leukemia or lymphoma. https://www.clinicaltrials.gov/ct2/show/NCT04037566 .

87 Shui J.W. Boomer J.S. Han J. Xu J. Dement G.A. Zhou G. Tan T.H. Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses Nat. Immunol. 8 2007 84 91 17115060 10.1038/ni1416

88 Alzabin S. Pyarajan S. Yee H. Kiefer F. Suzuki A. Burakoff S. Sawasdikosol S. Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response Cancer Immunol. Immunother. 59 2010 419 429 19787351 10.1007/s00262-009-0761-0 PMC2798028

89 Liu J. Curtin J. You D. Hillerman S. Li-Wang B. Eraslan R. Xie J. Swanson J. Ho C.P. Oppenheimer S. Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance PLoS ONE 14 2019 e0212670 30913212 10.1371/journal.pone.0212670 PMC6435129

90 Hernandez S. Qing J. Thibodeau R.H. Du X. Park S. Lee H.M. Xu M. Oh S. Navarro A. Roose-Girma M. The kinase activity of hematopoietic progenitor kinase 1 is essential for the regulation of T cell function Cell Rep. 25 2018 80 94 30282040 10.1016/j.celrep.2018.09.012

91 Zhang W. Shi L. Zhao Z. Du P. Ye X. Li D. Cai Z. Han J. Cai J. Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer Cancer Chemother. Pharmacol. 83 2019 911 920 30848330 10.1007/s00280-019-03800-x

92 Shi L. Meng T. Zhao Z. Han J. Zhang W. Gao F. Cai J. CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes Gene 636 2017 36 41 28888577 10.1016/j.gene.2017.09.010

93 Jung I.Y. Kim Y.Y. Yu H.S. Lee M. Kim S. Lee J. CRISPR/Cas9-mediated knockout of DGK improves antitumor activities of human T cells Cancer Res. 78 2018 4692 4703 29967261 10.1158/0008-5472.CAN-18-0030

94 Zhong X.-P. Hainey E.A. Olenchock B.A. Jordan M.S. Maltzman J.S. Nichols K.E. Shen H. Koretzky G.A. Enhanced T cell responses due to diacylglycerol kinase ζ deficiency Nat. Immunol. 4 2003 882 890 12883552 10.1038/ni958

95 Zhang Y. Zhang X. Cheng C. Mu W. Liu X. Li N. Wei X. Liu X. Xia C. Wang H. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells Front. Med. 11 2017 554 562 28625015 10.1007/s11684-017-0543-6

96 Singh N. Shi J. June C.H. Ruella M. Genome-editing technologies in adoptive T cell immunotherapy for cancer Curr. Hematol. Malig. Rep. 12 2017 522 529 29039115 10.1007/s11899-017-0417-7 PMC5709224

97 Torikai H. Cooper L.J. Translational implications for off-the-shelf immune cells expressing chimeric antigen receptors mol. ther. 24 2016 1178 1186 27203439 10.1038/mt.2016.106 PMC5088751

98 Yang Y. Jacoby E. Fry T.J. Challenges and opportunities of allogeneic donor-derived CAR T cells Curr. Opin. Hematol. 22 2015 509 515 26390167 10.1097/MOH.0000000000000181 PMC4636084

99 Torikai H. Reik A. Liu P.Q. Zhou Y. Zhang L. Maiti S. Huls H. Miller J.C. Kebriaei P. Rabinovich B. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR Blood 119 2012 5697 5705 22535661 10.1182/blood-2012-01-405365 PMC3382929

100 Poirot L. Philip B. Schiffer-Mannioui C. Le Clerre D. Chion-Sotinel I. Derniame S. Potrel P. Bas C. Lemaire L. Galetto R. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies Cancer Res. 75 2015 3853 3864 26183927 10.1158/0008-5472.CAN-14-3321

101 Georgiadis C. Preece R. Nickolay L. Etuk A. Petrova A. Ladon D. Danyi A. Humphryes-Kirilov N. Ajetunmobi A. Kim D. Long terminal repeat CRISPR-CAR-coupled “universal” T cells mediate potent anti-leukemic effects Mol. Ther. 26 2018 1215 1227 29605708 10.1016/j.ymthe.2018.02.025 PMC5993944

102 Qasim W. Zhan H. Samarasinghe S. Adams S. Amrolia P. Stafford S. Butler K. Rivat C. Wright G. Somana K. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells Sci. Transl. Med. 9 2017 eaaj2013 28123068 10.1126/scitranslmed.aaj2013

103 Servier (Institut de Recherches Internationales Servier); ADIR, a Servier Group company (2016). Study of UCART19 in pediatric patients with relapsed/refractory b acute lymphoblastic leukemia. https://clinicaltrials.gov/ct2/show/NCT02808442 .

104 Servier (Institut de Recherches Internationales Servier); ADIR, a Servier Group company (2016). Dose escalation study of UCART19 in adult patients with relapsed refractory B-cell acute lymphoblastic leukaemia. https://clinicaltrials.gov/ct2/show/NCT02746952 .

105 Allogene Therapeutics (2019). Safety and efficacy of ALLO-501 Anti-CD19 allogeneic CAR T cells in adults with relapsed/refractory large B cell or follicular lymphoma (ALPHA). https://clinicaltrials.gov/ct2/show/NCT03939026 .

106 Allogene Therapeutics (2019). Safety and efficacy of ALLO-715 BCMA allogenic CAR T cells in in adults with relapsed or refractory multiple myeloma (UNIVERSAL). https://clinicaltrials.gov/ct2/show/NCT04093596 .

107 Servier (Institut de Recherches Internationales Servier); ADIR, a Servier Group company (2016). A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19/ALLO-501. https://clinicaltrials.gov/ct2/show/NCT02735083 .

108 Ren J. Zhang X. Liu X. Fang C. Jiang S. June C.H. Zhao Y. A versatile system for rapid multiplex genome-edited CAR T cell generation Oncotarget 8 2017 17002 17011 28199983 10.18632/oncotarget.15218 PMC5370017

109 Ren J. Liu X. Fang C. Jiang S. June C.H. Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition Clin. Cancer Res. 23 2017 2255 2266 27815355 10.1158/1078-0432.CCR-16-1300 PMC5413401

110 Liu X. Zhang Y. Cheng C. Cheng A.W. Zhang X. Li N. Xia C. Wei X. Liu X. Wang H. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells Cell Res. 27 2017 154 157 27910851 10.1038/cr.2016.142 PMC5223227

111 Choi B.D. Yu X. Castano A.P. Darr H. Henderson D.B. Bouffard A.A. Larson R.C. Scarfò I. Bailey S.R. Gerhard G.M. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma J. Immunother. Cancer 7 2019 304 31727131 10.1186/s40425-019-0806-7 PMC6857271

112 Weidong, H.; Chinese PLA General Hospital (2017). A study evaluating UCART019 in patients with relapsed or refractory CD19 + leukemia and lymphoma. https://clinicaltrials.gov/ct2/show/NCT03166878 .

113 Eyquem J. Mansilla-Soto J. Giavridis T. van der Stegen S.J. Hamieh M. Cunanan K.M. Odak A. Gönen M. Sadelain M. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection Nature 543 2017 113 117 28225754 10.1038/nature21405 PMC5558614

114 Roth T.L. Puig-Saus C. Yu R. Shifrut E. Carnevale J. Li P.J. Hiatt J. Saco J. Krystofinski P. Li H. Reprogramming human T cell function and specificity with non-viral genome targeting Nature 559 2018 405 409 29995861 10.1038/s41586-018-0326-5 PMC6239417

115 CRISPR Therapeutics AG (2019). A safety and efficacy study evaluating CTX110 in subjects with relapsed or refractory B-cell malignancies. https://clinicaltrials.gov/ct2/show/NCT04035434 .

116 CRISPR Therapeutics AG (2020). A safety and efficacy study evaluating CTX120 in subjects with relapsed or refractory multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT04244656 .

117 Xu, K.L., and Zheng, J.N.; Nanjing Bioheng Biotech Co., Ltd. (2019). CTA101 UCAR-T cell injection for treatment of relapsed or refractory CD19 + B-cell acute lymphoblastic leukemia. https://clinicaltrials.gov/ct2/show/NCT04154709 .

118 Cellectis S.A. (2019). Phase I study of UCART22 in patients with relapsed or refractory CD22 + B-cell acute lymphoblastic leukemia (BALLI-01). https://clinicaltrials.gov/ct2/show/NCT04150497 .

119 The First Affiliated Hospital with Nanjing Medical University; Nanjing Bioheng Biotech Co., Ltd. (2019). CTA101 in the treatment of relapsed or refractory diffuse large B-cell lymphoma. https://clinicaltrials.gov/ct2/show/NCT04026100 .

120 Weidong, H.; Chinese PLA General Hospital (2018). A feasibility and safety study of universal dual specificity CD19 and CD20 or CD22 CAR-T cell immunotherapy for relapsed or refractory leukemia and lymphoma. https://clinicaltrials.gov/ct2/show/NCT03398967 .

121 Cellectis S.A. (2017). Study evaluating safety and efficacy of UCART123 in patients with relapsed/ refractory acute myeloid leukemia. https://clinicaltrials.gov/ct2/show/NCT03190278 .

122 Cellectis S.A. (2019). Study evaluating safety and efficacy of UCART targeting CS1 in patients with relapsed/refractory multiple myeloma (MELANI-01). https://clinicaltrials.gov/ct2/show/NCT04142619 .

123 Zhang, X.; Gracell Biotechnologies (Shanghai) Co., Ltd.; 920th Hospital of Joint Logistics Support Force; The Second Affiliated Hospital of Chongqing Medical University; The Affiliated Hospital of Guizhou Medical University; Central South University; The First Affiliated Hospital of Kunming Medical College; The General Hospital of Western Theater Command; Second Affiliated Hospital of Xi’an Jiaotong University; Nanfang Hospital of Southern Medical University; Fujian Medical University Union Hospital; The First Affiliated Hospital of Anhui Medical University; Tang-Du Hospital (2020). Anti-CD19 U-CAR-T cell therapy for B cell hematologic malignancies. https://clinicaltrials.gov/ct2/show/NCT04264039 .

124 Xiang, X.; Gracell Biotechnologies (Shanghai) Co., Ltd.; 920th Hospital of Joint Logistics Support Force; The Second Affiliated Hospital of Chongqing Medical University; The Affiliated Hospital of Guizhou Medical University; Central South University; The First Affiliated Hospital of Kunming Medical College; The General Hospital of Western Theater Command; Second Affiliated Hospital of Xi’an Jiaotong University; Nanfang Hospital of Southern Medical University; Fujian Medical University Union Hospital; The First Affiliated Hospital of Anhui Medical University; Tang-Du Hospital (2020). Anti-CD7 U-CAR-T cell therapy for T/NK cell hematologic malignancies. https://clinicaltrials.gov/ct2/show/NCT04264078 .

125 Shanghai Bioray Laboratory Inc.; Shanghai Tongji Hospital, Tongji University School of Medicine; Second Xiangya Hospital of Central South University (2018). Efficacy and safety evaluation of BCMA-UCART. https://clinicaltrials.gov/ct2/show/NCT03752541 .

126 Shanghai Bioray Laboratory Inc.; The First Affiliated Hospital of Zhengzhou University; Second Xiangya Hospital of Central South University; Shanghai 10th People’s Hospital (2017). Safety and efficacy evaluation of CD19-UCART. https://clinicaltrials.gov/ct2/show/NCT03229876 .

127 Shanghai Longyao Biotechnology Inc. Ltd. (2019). The clinical study of CD19 UCAR-T cells in patients with B-cell acute lymphoblastic leukemia (B-ALL). https://clinicaltrials.gov/ct2/show/NCT04166838 .

128 Ma H. Padmanabhan Iyer S. Parmar S. Gong Y. Adoptive cell therapy for acute myeloid leukemia Leuk. Lymphoma 60 2019 1370 1380 30628504 10.1080/10428194.2018.1553300

129 Kenderian S.S. Ruella M. Shestova O. Klichinsky M. Aikawa V. Morrissette J.J. Scholler J. Song D. Porter D.L. Carroll M. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia Leukemia 29 2015 1637 1647 25721896 10.1038/leu.2015.52 PMC4644600

130 Gill S. Tasian S.K. Ruella M. Shestova O. Li Y. Porter D.L. Carroll M. Danet-Desnoyers G. Scholler J. Grupp S.A. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells Blood 123 2014 2343 2354 24596416 10.1182/blood-2013-09-529537 PMC3983612

131 Kim M.Y. Yu K.R. Kenderian S.S. Ruella M. Chen S. Shin T.H. Aljanahi A.A. Schreeder D. Klichinsky M. Shestova O. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia Cell 173 2018 1439 1453.e19 29856956 10.1016/j.cell.2018.05.013 PMC6003425

132 Knipping F. Osborn M.J. Petri K. Tolar J. Glimm H. von Kalle C. Schmidt M. Gabriel R. Genome-wide specificity of highly efficient TALENs and CRISPR/Cas9 for T cell receptor modification Mol. Ther. Methods Clin. Dev. 4 2017 213 224 28345006 10.1016/j.omtm.2017.01.005 PMC5363317

133 University of Pennsylvania (2018). NY-ESO-1-redirected CRISPR (TCRendo and PD1) edited T cells (NYCE T cells). https://clinicaltrials.gov/ct2/show/NCT03399448 .

134 Weidong, H.; Chinese PLA General Hospital (2018). Study of CRISPR-Cas9 mediated PD-1 and TCR gene-knocked out mesothelin-directed CAR-T cells in patients with mesothelin positive multiple solid tumors. https://clinicaltrials.gov/ct2/show/NCT03545815 .

135 Stadtmauer E.A. Fraietta J.A. Davis M.M. Cohen A.D. Weber K.L. Lancaster E. Mangan P.A. Kulikovskaya I. Gupta M. Chen F. CRISPR-engineered T cells in patients with refractory cancer Science 367 2020 eaba7365 32029687 10.1126/science.aba7365 PMC11249135

136 Rapoport A.P. Stadtmauer E.A. Binder-Scholl G.K. Goloubeva O. Vogl D.T. Lacey S.F. Badros A.Z. Garfall A. Weiss B. Finklestein J. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma Nat. Med. 21 2015 914 921 26193344 10.1038/nm.3910 PMC4529359

137 Robbins P.F. Kassim S.H. Tran T.L. Crystal J.S. Morgan R.A. Feldman S.A. Yang J.C. Dudley M.E. Wunderlich J.R. Sherry R.M. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response Clin. Cancer Res. 21 2015 1019 1027 25538264 10.1158/1078-0432.CCR-14-2708 PMC4361810

138 D’Angelo S.P. Melchiori L. Merchant M.S. Bernstein D. Glod J. Kaplan R. Grupp S. Tap W.D. Chagin K. Binder G.K. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259 T cells in synovial sarcoma Cancer Discov. 8 2018 944 957 29891538 10.1158/2159-8290.CD-17-1417 PMC8092079

139 Alcantara M. Tesio M. June C.H. Houot R. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells Leukemia 32 2018 2307 2315 30315238 10.1038/s41375-018-0285-8 PMC7433349

140 Zhou S. Zhu X. Shen N. Li Q. Wang N. You Y. Zhong Z. Cheng F. Zou P. Zhu X. T cells expressing CD26-specific chimeric antigen receptors exhibit extensive self-antigen-driven fratricide Immunopharmacol. Immunotoxicol. 41 2019 490 496 31303072 10.1080/08923973.2019.1637889

141 Leisegang M. Wilde S. Spranger S. Milosevic S. Frankenberger B. Uckert W. Schendel D.J. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors J. Clin. Invest. 120 2010 3869 3877 20978348 10.1172/JCI43437 PMC2964986

142 Cooper M.L. Choi J. Staser K. Ritchey J.K. Devenport J.M. Eckardt K. Rettig M.P. Wang B. Eissenberg L.G. Ghobadi A. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies Leukemia 32 2018 1970 1983 29483708 10.1038/s41375-018-0065-5 PMC6102094

143 Gomes-Silva D. Srinivasan M. Sharma S. Lee C.M. Wagner D.L. Davis T.H. Rouce R.H. Bao G. Brenner M.K. Mamonkin M. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies Blood 130 2017 285 296 28539325 10.1182/blood-2017-01-761320 PMC5520470

144 Rouce, R.; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine (2018). Cell therapy for high risk T-cell malignancies using CD7-specific CAR expressed on autologous T cells. https://clinicaltrials.gov/ct2/show/NCT03690011 .

145 Jemal A. Bray F. Center M.M. Ferlay J. Ward E. Forman D. Global cancer statistics CA Cancer J. Clin. 61 2011 69 90 21296855 10.3322/caac.20107

146 Bruni L. Diaz M. Barrionuevo-Rosas L. Herrero R. Bray F. Bosch F.X. de Sanjosé S. Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis Lancet Glob. Health 4 2016 e453 e463 27340003 10.1016/S2214-109X(16)30099-7

147 Crosbie E.J. Einstein M.H. Franceschi S. Kitchener H.C. Human papillomavirus and cervical cancer Lancet 382 2013 889 899 23618600 10.1016/S0140-6736(13)60022-7

148 Howlader, N., Noone, A.M., Krapcho, M., Miller, D., Bishop, K., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J., and Cronin, K.A., eds. (2018). SEER Cancer Statistics Review, 1975–2014 (National Cancer Institute), https://seer.cancer.gov/csr/1975_2014/ .

149 zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application Nat. Rev. Cancer 2 2002 342 350 12044010 10.1038/nrc798

150 Sima N. Wang W. Kong D. Deng D. Xu Q. Zhou J. Xu G. Meng L. Lu Y. Wang S. Ma D. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53 Apoptosis 13 2008 273 281 18060502 10.1007/s10495-007-0163-8

151 Wang W. Sima N. Kong D. Luo A. Gao Q. Liao S. Li W. Han L. Wang J. Wang S. Selective targeting of HPV-16 E6/E7 in cervical cancer cells with a potent oncolytic adenovirus and its enhanced effect with radiotherapy in vitro and vivo Cancer Lett. 291 2010 67 75 19903581 10.1016/j.canlet.2009.09.022

152 Almeida A.M. Queiroz J.A. Sousa F. Sousa Â. Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins Drug Discov. Today 24 2019 2044 2057 31398400 10.1016/j.drudis.2019.07.011

153 Zheng Z.M. Tang S. Tao M. Development of resistance to RNAi in mammalian cells Ann. N Y Acad. Sci. 1058 2005 105 118 16394130 10.1196/annals.1359.019 PMC1462965

154 Ding W. Hu Z. Zhu D. Jiang X. Yu L. Wang X. Zhang C. Wang L. Ji T. Li K. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells Clin. Cancer Res. 20 2014 6495 6503 25336692 10.1158/1078-0432.CCR-14-0250

155 Hu Z. Ding W. Zhu D. Yu L. Jiang X. Wang X. Zhang C. Wang L. Ji T. Liu D. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy J. Clin. Invest. 125 2015 425 436 25500889 10.1172/JCI78206 PMC4382249

156 Shankar S. Prasad D. Sanawar R. Das A.V. Pillai M.R. TALEN based HPV-E7 editing triggers necrotic cell death in cervical cancer cells Sci. Rep. 7 2017 5500 28710417 10.1038/s41598-017-05696-0 PMC5511212

157 Zhen S. Hua L. Takahashi Y. Narita S. Liu Y.H. Li Y. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9 Biochem. Biophys. Res. Commun. 450 2014 1422 1426 25044113 10.1016/j.bbrc.2014.07.014

158 Hu Z. Yu L. Zhu D. Ding W. Wang X. Zhang C. Wang L. Jiang X. Shen H. He D. Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells BioMed Res. Int. 2014 2014 612823 25136604 10.1155/2014/612823 PMC4127252

159 Kennedy E.M. Kornepati A.V. Goldstein M. Bogerd H.P. Poling B.C. Whisnant A.W. Kastan M.B. Cullen B.R. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease J. Virol. 88 2014 11965 11972 25100830 10.1128/JVI.01879-14 PMC4178730

160 Ma, D.; Huazhong University of Science and Technology (2017). Study of molecular-targeted therapy using zinc finger nuclease in cervical precancerous lesions. https://clinicaltrials.gov/ct2/show/NCT02800369 .

161 Ma, D.; Huazhong University of Science and Technology (2017). Study of targeted therapy using transcription activator-like effector nucleases in cervical precancerous lesions. https://clinicaltrials.gov/ct2/show/NCT03226470 .

162 Zheng, H.; First Affiliated Hospital, Sun Yat-Sen University; Jingchu University of Technology (2017). A safety and efficacy study of TALEN and CRISPR/Cas9 in the treatment of HPV-related cervical intraepithelial neoplasia. https://clinicaltrials.gov/ct2/show/NCT03057912 .

163 Zhen S. Lu J.J. Wang L.J. Sun X.M. Zhang J.Q. Li X. Luo W.J. Zhao L. In vitro and in vivo synergistic therapeutic effect of cisplatin with human papillomavirus16 E6/E7 CRISPR/Cas9 on cervical cancer cell line Transl. Oncol. 9 2016 498 504 27816686 10.1016/j.tranon.2016.10.002 PMC5094426

164 Münger K. The role of human papillomaviruses in human cancers Front. Biosci. 7 2002 d641 d649 11861215 10.2741/a800

165 Lin S.R. Yang H.C. Kuo Y.T. Liu C.J. Yang T.Y. Sung K.C. Lin Y.Y. Wang H.Y. Wang C.C. Shen Y.C. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo Mol. Ther. Nucleic Acids 3 2014 e186 25137139 10.1038/mtna.2014.38 PMC4221598

166 Seeger C. Sohn J.A. Targeting hepatitis B virus with CRISPR/Cas9 Mol. Ther. Nucleic Acids 3 2014 e216 25514649 10.1038/mtna.2014.68 PMC4272409

167 Kennedy E.M. Cullen B.R. Bacterial CRISPR/Cas DNA endonucleases: a revolutionary technology that could dramatically impact viral research and treatment Virology 479–480 2015 213 220 10.1016/j.virol.2015.02.024 PMC4424069 25759096

168 Zhen S. Hua L. Liu Y.H. Gao L.C. Fu J. Wan D.Y. Dong L.H. Song H.F. Gao X. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus Gene Ther. 22 2015 404 412 25652100 10.1038/gt.2015.2

169 Li H. Sheng C. Wang S. Yang L. Liang Y. Huang Y. Liu H. Li P. Yang C. Yang X. Removal of integrated hepatitis B virus DNA using CRISPR-Cas9 Front. Cell. Infect. Microbiol. 7 2017 91 28382278 10.3389/fcimb.2017.00091 PMC5360708

170 Scott T. Moyo B. Nicholson S. Maepa M.B. Watashi K. Ely A. Weinberg M.S. Arbuthnot P. ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells Sci. Rep. 7 2017 7401 28785016 10.1038/s41598-017-07642-6 PMC5547162

171 Liu Y. Zhao M. Gong M. Xu Y. Xie C. Deng H. Li X. Wu H. Wang Z. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus Antiviral Res. 152 2018 58 67 29458131 10.1016/j.antiviral.2018.02.011

172 Jiang C. Mei M. Li B. Zhu X. Zu W. Tian Y. Wang Q. Guo Y. Dong Y. Tan X. A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo Cell Res. 27 2017 440 443 28117345 10.1038/cr.2017.16 PMC5339835

173 Wang J. Quake S.R. RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection Proc. Natl. Acad. Sci. USA 111 2014 13157 13162 25157128 10.1073/pnas.1410785111 PMC4246930

174 Yuen K.S. Chan C.P. Wong N.M. Ho C.H. Ho T.H. Lei T. Deng W. Tsao S.W. Chen H. Kok K.H. Jin D.Y. CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells J. Gen. Virol. 96 2015 626 636 25502645 10.1099/jgv.0.000012

175 van Diemen F.R. Kruse E.M. Hooykaas M.J. Bruggeling C.E. Schürch A.C. van Ham P.M. Imhof S.M. Nijhuis M. Wiertz E.J. Lebbink R.J. CRISPR/Cas9-mediated genome editing of herpesviruses limits productive and latent infections PLoS Pathog. 12 2016 e1005701 27362483 10.1371/journal.ppat.1005701 PMC4928872

176 Yuen K.S. Wang Z.M. Wong N.M. Zhang Z.Q. Cheng T.F. Lui W.Y. Chan C.P. Jin D.Y. Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR/Cas9 Virus Res. 244 2018 296 303 28456574 10.1016/j.virusres.2017.04.019

177 de Buhr H. Lebbink R.J. Harnessing CRISPR to combat human viral infections Curr. Opin. Immunol. 54 2018 123 129 30056335 10.1016/j.coi.2018.06.002

178 Mbonye U. Karn J. The molecular basis for human immunodeficiency virus latency Annu. Rev. Virol. 4 2017 261 285 28715973 10.1146/annurev-virology-101416-041646

179 Chun T.W. Davey R.T. Jr. Engel D. Lane H.C. Fauci A.S. Re-emergence of HIV after stopping therapy Nature 401 1999 874 875 10553903 10.1038/44755

180 Iacob S.A. Iacob D.G. Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations Front. Pharmacol. 8 2017 831 29218008 10.3389/fphar.2017.00831 PMC5703840

181 Allers K. Hütter G. Hofmann J. Loddenkemper C. Rieger K. Thiel E. Schneider T. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation Blood 117 2011 2791 2799 21148083 10.1182/blood-2010-09-309591

182 Hütter G. Nowak D. Mossner M. Ganepola S. Müssig A. Allers K. Schneider T. Hofmann J. Kücherer C. Blau O. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation N. Engl. J. Med. 360 2009 692 698 19213682 10.1056/NEJMoa0802905

183 Wu L. Gerard N.P. Wyatt R. Choe H. Parolin C. Ruffing N. Borsetti A. Cardoso A.A. Desjardin E. Newman W. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 Nature 384 1996 179 183 8906795 10.1038/384179a0

184 Gupta R.K. Abdul-Jawad S. McCoy L.E. Mok H.P. Peppa D. Salgado M. Martinez-Picado J. Nijhuis M. Wensing A.M.J. Lee H. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation Nature 568 2019 244 248 30836379 10.1038/s41586-019-1027-4 PMC7275870

185 Ioannidis J.P. Rosenberg P.S. Goedert J.J. Ashton L.J. Benfield T.L. Buchbinder S.P. Coutinho R.A. Eugen-Olsen J. Gallart T. Katzenstein T.L. International Meta-Analysis of HIV Host Genetics Effects of CCR5-Δ32 , CCR2-64I , and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data Ann. Intern. Med. 135 2001 782 795 11694103 10.7326/0003-4819-135-9-200111060-00008

186 Ioannidis J.P. Contopoulos-Ioannidis D.G. Rosenberg P.S. Goedert J.J. De Rossi A. Espanol T. Frenkel L. Mayaux M.J. Newell M.L. Pahwa S.G. HIV Host Genetics International Meta-Analysis Group Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis AIDS 17 2003 1631 1638 12853745 10.1097/01.aids.0000060411.18106.0f

187 Mulherin S.A. O’Brien T.R. Ioannidis J.P. Goedert J.J. Buchbinder S.P. Coutinho R.A. Jamieson B.D. Meyer L. Michael N.L. Pantaleo G. International Meta-Analysis of HIV Host Genetics Effects of CCR5-delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection AIDS 17 2003 377 387 12556692 10.1097/01.aids.0000050783.28043.3e

188 Perez E.E. Wang J. Miller J.C. Jouvenot Y. Kim K.A. Liu O. Wang N. Lee G. Bartsevich V.V. Lee Y.L. Establishment of HIV-1 resistance in CD4 + T cells by genome editing using zinc-finger nucleases Nat. Biotechnol. 26 2008 808 816 18587387 10.1038/nbt1410 PMC3422503

189 University of Pennsylvania; Sangamo Therapeutics (2009). Autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases SB-728 for HIV (zinc-finger). https://clinicaltrials.gov/ct2/show/NCT00842634 .

190 Sangamo Therapeutics (2010). Phase 1 dose escalation study of autologous t-cells genetically modified at the CCR5 gene by zinc finger nucleases in HIV-infected patients. https://clinicaltrials.gov/ct2/show/NCT01044654 .

191 Sangamo Therapeutics (2014). Repeat doses of SB-728mR-T after cyclophosphamide conditioning in HIV-infected subjects on HAART. https://clinicaltrials.gov/ct2/show/NCT02225665 .

192 University of Pennsylvania; National Institute of Allergy and Infectious Diseases (NIAID) (2015). A phase I study of T-cells genetically modified at the CCR5 gene by zinc finger nucleases SB-728mR in HIV-infected patients. https://clinicaltrials.gov/ct2/show/NCT02388594 .

193 Sangamo Therapeutics (2012). Dose escalation study of cyclophosphamide in HIV-infected subjects on HAART receiving SB-728-T. https://clinicaltrials.gov/ct2/show/NCT01543152 .

194 Smith, C.; Case Western Reserve Univeristy; University of California, San Francisco; University of Cincinnati (2018). CCR5-modified CD4 + T cells for HIV infection (TRAILBLAZER). https://clinicaltrials.gov/ct2/show/NCT03666871 .

195 Sangamo Therapeutics (2014). Study of autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases in HIV-infected subjects. https://clinicaltrials.gov/ct2/show/NCT01252641 .

196 Tebas P. Stein D. Tang W.W. Frank I. Wang S.Q. Lee G. Spratt S.K. Surosky R.T. Giedlin M.A. Nichol G. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV N. Engl. J. Med. 370 2014 901 910 24597865 10.1056/NEJMoa1300662 PMC4084652

197 Sangamo Therapeutics (2019). Long-term follow-up of HIV subjects exposed to SB-728-T or SB-728mR-T. https://clinicaltrials.gov/ct2/show/NCT04201782 .

198 Wang C.X. Cannon P.M. Clinical applications of genome editing to HIV cure AIDS Patient Care STDS 30 2016 539 544 27854119 10.1089/apc.2016.0233 PMC5144849

199 Wang C.X. Cannon P.M. The clinical applications of genome editing in HIV Blood 127 2016 2546 2552 27053530 10.1182/blood-2016-01-678144 PMC4882804

200 Li L. Krymskaya L. Wang J. Henley J. Rao A. Cao L.F. Tran C.A. Torres-Coronado M. Gardner A. Gonzalez N. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases Mol. Ther. 21 2013 1259 1269 23587921 10.1038/mt.2013.65 PMC3677314

201 Wang J. Exline C.M. DeClercq J.J. Llewellyn G.N. Hayward S.B. Li P.W. Shivak D.A. Surosky R.T. Gregory P.D. Holmes M.C. Cannon P.M. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors Nat. Biotechnol. 33 2015 1256 1263 26551060 10.1038/nbt.3408 PMC4842001

202 Holt N. Wang J. Kim K. Friedman G. Wang X. Taupin V. Crooks G.M. Kohn D.B. Gregory P.D. Holmes M.C. Cannon P.M. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo Nat. Biotechnol. 28 2010 839 847 20601939 10.1038/nbt.1663 PMC3080757

203 Krishnan, A.Y.; City of Hope Medical Center; Sangamo Therapeutics;California Institute for Regenerative Medicine (CIRM) (2015). Safety study of zinc finger nuclease CCR5-modified hematopoietic stem/progenitor cells in HIV-1 infected patients. https://clinicaltrials.gov/ct2/show/NCT02500849 .

204 Hu, C.; Affiliated Hospital to Academy of Military Medical Sciences;Peking University; Capital Medical University (2017). Safety of transplantation of CRISPR CCR5 modified CD34 + cells in HIV-infected subjects with hematological malignances. https://clinicaltrials.gov/ct2/show/NCT03164135 .

205 Maldini C.R. Ellis G.I. Riley J.L. CAR T cells for infection, autoimmunity and allotransplantation Nat. Rev. Immunol. 18 2018 605 616 30046149 10.1038/s41577-018-0042-2 PMC6505691

206 Tebas, P; University of Pennsylvania (2018). CD4 CAR + ZFN-modified T cells in HIV therapy. https://clinicaltrials.gov/ct2/show/NCT03617198 .

207 Oh D.Y. Jessen H. Kücherer C. Neumann K. Oh N. Poggensee G. Bartmeyer B. Jessen A. Pruss A. Schumann R.R. Hamouda O. CCR5Δ32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Δ32 homozygous individual PLoS ONE 3 2008 e2747 18648518 10.1371/journal.pone.0002747 PMC2453227

208 Kordelas L. Verheyen J. Beelen D.W. Horn P.A. Heinold A. Kaiser R. Trenschel R. Schadendorf D. Dittmer U. Esser S. Essen HIV AlloSCT Group Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation N. Engl. J. Med. 371 2014 880 882 10.1056/NEJMc1405805 25162903

209 Henrich T.J. Hanhauser E. Hu Z. Stellbrink H.J. Noah C. Martin J.N. Deeks S.G. Kuritzkes D.R. Pereyra F. Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32 AIDS 29 2015 867 876 25730507 10.1097/QAD.0000000000000629 PMC4473772

210 Murray A.J. Kwon K.J. Farber D.L. Siliciano R.F. The latent reservoir for HIV-1: how immunologic memory and clonal expansion contribute to HIV-1 persistence J. Immunol. 197 2016 407 417 27382129 10.4049/jimmunol.1600343 PMC4936486

211 Ebina H. Misawa N. Kanemura Y. Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus Sci. Rep. 3 2013 2510 23974631 10.1038/srep02510 PMC3752613

212 Hu W. Kaminski R. Yang F. Zhang Y. Cosentino L. Li F. Luo B. Alvarez-Carbonell D. Garcia-Mesa Y. Karn J. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection Proc. Natl. Acad. Sci. USA 111 2014 11461 11466 25049410 10.1073/pnas.1405186111 PMC4128125

213 Zhu W. Lei R. Le Duff Y. Li J. Guo F. Wainberg M.A. Liang C. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA Retrovirology 12 2015 22 25808449 10.1186/s12977-015-0150-z PMC4359768

214 Kaminski R. Chen Y. Fischer T. Tedaldi E. Napoli A. Zhang Y. Karn J. Hu W. Khalili K. Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing Sci. Rep. 6 2016 22555 26939770 10.1038/srep22555 PMC4778041

215 Wang G. Zhao N. Berkhout B. Das A.T. A combinatorial CRISPR-Cas9 attack on HIV-1 DNA extinguishes all infectious provirus in infected T cell cultures Cell Rep. 17 2016 2819 2826 27974196 10.1016/j.celrep.2016.11.057

216 Liao H.K. Gu Y. Diaz A. Marlett J. Takahashi Y. Li M. Suzuki K. Xu R. Hishida T. Chang C.J. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells Nat. Commun. 6 2015 6413 25752527 10.1038/ncomms7413

217 Yin C. Zhang T. Li F. Yang F. Putatunda R. Young W.B. Khalili K. Hu W. Zhang Y. Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS AIDS 30 2016 1163 1174 26990633 10.1097/QAD.0000000000001079 PMC4851589

218 Lebbink R.J. de Jong D.C. Wolters F. Kruse E.M. van Ham P.M. Wiertz E.J. Nijhuis M. A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape Sci. Rep. 7 2017 41968 28176813 10.1038/srep41968 PMC5296774

219 Yin L. Hu S. Mei S. Sun H. Xu F. Li J. Zhu W. Liu X. Zhao F. Zhang D. CRISPR/Cas9 inhibits multiple steps of HIV-1 unfection Hum. Gene Ther. 29 2018 1264 1276 29644868 10.1089/hum.2018.018

220 Xiao Q. Guo D. Chen S. Application of CRISPR/Cas9-based gene editing in HIV-1/AIDS therapy Front. Cell. Infect. Microbiol. 9 2019 69 30968001 10.3389/fcimb.2019.00069 PMC6439341

221 Tsukamoto T. Gene therapy approaches to functional cure and protection of hematopoietic potential in HIV infection Pharmaceutics 11 2019 E114 30862061 10.3390/pharmaceutics11030114 PMC6470728

222 Bobbin M.L. Burnett J.C. Rossi J.J. RNA interference approaches for treatment of HIV-1 infection Genome Med. 7 2015 50 26019725 10.1186/s13073-015-0174-y PMC4445287

223 Hartweger H. McGuire A.T. Horning M. Taylor J.J. Dosenovic P. Yost D. Gazumyan A. Seaman M.S. Stamatatos L. Jankovic M. Nussenzweig M.C. HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells J. Exp. Med. 216 2019 1301 1310 30975893 10.1084/jem.20190287 PMC6547862

224 Voss J.E. Gonzalez-Martin A. Andrabi R. Fuller R.P. Murrell B. McCoy L.E. Porter K. Huang D. Li W. Sok D. Reprogramming the antigen specificity of B cells using genome-editing technologies eLife 8 2019 e42995 30648968 10.7554/eLife.42995 PMC6355199

225 Moffett H.F. Harms C.K. Fitzpatrick K.S. Tooley M.R. Boonyaratanakornkit J. Taylor J.J. B cells engineered to express pathogen-specific antibodies protect against infection Sci. Immunol. 4 2019 eaax0644 31101673 10.1126/sciimmunol.aax0644 PMC6913193

226 Weatherall D.J. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias Nat. Rev. Genet. 2 2001 245 255 11283697 10.1038/35066048

227 Bank A. Regulation of human fetal hemoglobin: new players, new complexities Blood 107 2006 435 443 16109777 10.1182/blood-2005-05-2113 PMC1895603

228 Cappellini M.D. Porter J.B. Viprakasit V. Taher A.T. A paradigm shift on beta-thalassaemia treatment: how will we manage this old disease with new therapies? Blood Rev. 32 2018 300 311 29455932 10.1016/j.blre.2018.02.001

229 Shah F.T. Sayani F. Trompeter S. Drasar E. Piga A. Challenges of blood transfusions in β-thalassemia Blood Rev. 37 2019 100588 31324412 10.1016/j.blre.2019.100588

230 Bonifazi F. Conte R. Baiardi P. Bonifazi D. Felisi M. Giordano P. Giannuzzi V. Iacono A. Padula R. Pepe A. HTA-THAL Multiregional Registry Pattern of complications and burden of disease in patients affected by beta thalassemia major Curr. Med. Res. Opin. 33 2017 1525 1533 28471307 10.1080/03007995.2017.1326890

231 Telfer P. Update on survival in thalassemia major Hemoglobin 33 Suppl 1 2009 S76 S80 20001636 10.3109/03630260903347336

232 Locatelli F. Merli P. Strocchio L. Transplantation for thalassemia major: alternative donors Curr. Opin. Hematol. 23 2016 515 523 27537474 10.1097/MOH.0000000000000280

233 Tiercy J.M. Claas F. Impact of HLA diversity on donor selection in organ and stem cell transplantation Hum. Hered. 76 2013 178 186 24861862 10.1159/000358798

234 Strocchio L. Romano M. Cefalo M.G. Vinti L. Gaspari S. Locatelli F. Cord blood transplantation in children with hemoglobinopathies Expert Opin. Orphan Drugs 3 2015 1125 1136

235 Baronciani D. Angelucci E. Potschger U. Gaziev J. Yesilipek A. Zecca M. Orofino M.G. Giardini C. Al-Ahmari A. Marktel S. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000–2010 Bone Marrow Transplant. 51 2016 536 541 26752139 10.1038/bmt.2015.293

236 Piel F.B. Steinberg M.H. Rees D.C. Sickle cell disease N. Engl. J. Med. 376 2017 1561 1573 28423290 10.1056/NEJMra1510865

237 Kato G.J. Piel F.B. Reid C.D. Gaston M.H. Ohene-Frempong K. Krishnamurti L. Smith W.R. Panepinto J.A. Weatherall D.J. Costa F.F. Vichinsky E.P. Sickle cell disease Nat. Rev. Dis. Primers 4 2018 18010 29542687 10.1038/nrdp.2018.10

238 Leonard A. Tisdale J.F. Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced Expert Rev. Hematol. 11 2018 547 565 29883237 10.1080/17474086.2018.1486703 PMC8459571

239 Hsieh M.M. Fitzhugh C.D. Weitzel R.P. Link M.E. Coles W.A. Zhao X. Rodgers G.P. Powell J.D. Tisdale J.F. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype JAMA 312 2014 48 56 25058217 10.1001/jama.2014.7192 PMC4698790

240 Hsieh M.M. Kang E.M. Fitzhugh C.D. Link M.B. Bolan C.D. Kurlander R. Childs R.W. Rodgers G.P. Powell J.D. Tisdale J.F. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease N. Engl. J. Med. 361 2009 2309 2317 20007560 10.1056/NEJMoa0904971 PMC3627532

241 Fitzhugh C.D. Abraham A.A. Tisdale J.F. Hsieh M.M. Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions Hematol. Oncol. Clin. North Am. 28 2014 1171 1185 25459186 10.1016/j.hoc.2014.08.014 PMC4254544

242 Goodman M.A. Malik P. The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges Ther. Adv. Hematol. 7 2016 302 315 27695619 10.1177/2040620716653729 PMC5026290

243 Cavazzana-Calvo M. Payen E. Negre O. Wang G. Hehir K. Fusil F. Down J. Denaro M. Brady T. Westerman K. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia Nature 467 2010 318 322 20844535 10.1038/nature09328 PMC3355472

244 Ribeil J.A. Hacein-Bey-Abina S. Payen E. Magnani A. Semeraro M. Magrin E. Caccavelli L. Neven B. Bourget P. El Nemer W. Gene therapy in a patient with sickle cell disease N. Engl. J. Med. 376 2017 848 855 28249145 10.1056/NEJMoa1609677

245 Thompson A.A. Walters M.C. Kwiatkowski J. Rasko J.E.J. Ribeil J.A. Hongeng S. Magrin E. Schiller G.J. Payen E. Semeraro M. Gene therapy in patients with transfusion-dependent β-thalassemia N. Engl. J. Med. 378 2018 1479 1493 29669226 10.1056/NEJMoa1705342

246 Marktel S. Scaramuzza S. Cicalese M.P. Giglio F. Galimberti S. Lidonnici M.R. Calbi V. Assanelli A. Bernardo M.E. Rossi C. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia Nat. Med. 25 2019 234 241 30664781 10.1038/s41591-018-0301-6

247 Davé U.P. Jenkins N.A. Copeland N.G. Gene therapy insertional mutagenesis insights Science 303 2004 333 14726584 10.1126/science.1091667

248 Hacein-Bey Abina S. Gaspar H.B. Blondeau J. Caccavelli L. Charrier S. Buckland K. Picard C. Six E. Himoudi N. Gilmour K. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome JAMA 313 2015 1550 1563 25898053 10.1001/jama.2015.3253 PMC4942841

249 De Ravin S.S. Wu X. Moir S. Anaya-O’Brien S. Kwatemaa N. Littel P. Theobald N. Choi U. Su L. Marquesen M. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency Sci. Transl. Med. 8 2016 335ra57 10.1126/scitranslmed.aad8856 PMC5557273 27099176

250 Biffi A. Montini E. Lorioli L. Cesani M. Fumagalli F. Plati T. Baldoli C. Martino S. Calabria A. Canale S. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy Science 341 2013 1233158 23845948 10.1126/science.1233158

251 Sessa M. Lorioli L. Fumagalli F. Acquati S. Redaelli D. Baldoli C. Canale S. Lopez I.D. Morena F. Calabria A. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial Lancet 388 2016 476 487 27289174 10.1016/S0140-6736(16)30374-9

252 Eichler F. Duncan C. Musolino P.L. Orchard P.J. De Oliveira S. Thrasher A.J. Armant M. Dansereau C. Lund T.C. Miller W.P. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy N. Engl. J. Med. 377 2017 1630 1638 28976817 10.1056/NEJMoa1700554 PMC5708849

253 Ferrua F. Cicalese M.P. Galimberti S. Giannelli S. Dionisio F. Barzaghi F. Migliavacca M. Bernardo M.E. Calbi V. Assanelli A.A. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study Lancet Haematol. 6 2019 e239 e253 30981783 10.1016/S2352-3026(19)30021-3 PMC6494976

254 Mamcarz E. Zhou S. Lockey T. Abdelsamed H. Cross S.J. Kang G. Ma Z. Condori J. Dowdy J. Triplett B. Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1 N. Engl. J. Med. 380 2019 1525 1534 30995372 10.1056/NEJMoa1815408 PMC6636624

255 Cicalese M.P. Ferrua F. Castagnaro L. Rolfe K. De Boever E. Reinhardt R.R. Appleby J. Roncarolo M.G. Aiuti A. Gene therapy for adenosine deaminase deficiency: a comprehensive evaluation of short- and medium-term safety Mol. Ther. 26 2018 917 931 29433935 10.1016/j.ymthe.2017.12.022 PMC5910668

256 Thein S.L. Menzel S. Lathrop M. Garner C. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications Hum. Mol. Genet. 18 R2 2009 R216 R223 19808799 10.1093/hmg/ddp401 PMC2758709

257 Liu N. Hargreaves V.V. Zhu Q. Kurland J.V. Hong J. Kim W. Sher F. Macias-Trevino C. Rogers J.M. Kurita R. Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch Cell 173 2018 430 442.e17 29606353 10.1016/j.cell.2018.03.016 PMC5889339

258 Chen Z. Luo H.Y. Steinberg M.H. Chui D.H. BCL11A represses HBG transcription in K562 cells Blood Cells Mol. Dis. 42 2009 144 149 19153051 10.1016/j.bcmd.2008.12.003

259 Sankaran V.G. Xu J. Ragoczy T. Ippolito G.C. Walkley C.R. Maika S.D. Fujiwara Y. Ito M. Groudine M. Bender M.A. Developmental and species-divergent globin switching are driven by BCL11A Nature 460 2009 1093 1097 19657335 10.1038/nature08243 PMC3749913

260 Chang K.H. Smith S.E. Sullivan T. Chen K. Zhou Q. West J.A. Liu M. Liu Y. Vieira B.F. Sun C. Long-term engraftment and fetal globin induction upon BCL11A gene editing in bone-marrow-derived CD34 + hematopoietic stem and progenitor cells Mol. Ther. Methods Clin. Dev. 4 2017 137 148 28344999 10.1016/j.omtm.2016.12.009 PMC5363298

261 Smith E.C. Luc S. Croney D.M. Woodworth M.B. Greig L.C. Fujiwara Y. Nguyen M. Sher F. Macklis J.D. Bauer D.E. Orkin S.H. Strict in vivo specificity of the Bcl11a erythroid enhancer Blood 128 2016 2338 2342 27707736 10.1182/blood-2016-08-736249 PMC5106112

262 Psatha N. Reik A. Phelps S. Zhou Y. Dalas D. Yannaki E. Levasseur D.N. Urnov F.D. Holmes M.C. Papayannopoulou T. Disruption of the BCL11A erythroid enhancer reactivates fetal hemoglobin in erythroid cells of patients with β-thalassemia major Mol. Ther. Methods Clin. Dev. 10 2018 313 326 30182035 10.1016/j.omtm.2018.08.003 PMC6120587

263 Chapin, J.; Vertex Pharmaceuticals Incorporated; CRISPR Therapeutics (2018) A safety and efficacy study evaluating CTX001 in subjects with transfusion-dependent β-thalassemia. https://clinicaltrials.gov/ct2/show/NCT03655678 .

264 Schiller, G., Walters, M., Williams, D., and Smith, A; Sangamo Therapeutics; Sanofi. (2018). A study to assess the safety, tolerability, and efficacy of ST-400 for treatment of transfusion-dependent beta-thalassemia (TDT). https://clinicaltrials.gov/ct2/show/NCT03432364 .

265 Chapin, J.; Vertex Pharmaceuticals Incorporated; CRISPR Therapeutics (2018). A safety and efficacy study evaluating CTX001 in subjects with severe sickle cell disease. https://clinicaltrials.gov/ct2/show/NCT03745287 .

266 Sanofi; Bioverativ Therapeutics Inc. (2018). A study to assess the safety, tolerability, and efficacy of BIVV003 for autologous hematopoietic stem cell transplantation in patients with severe sickle cell disease (BIVV003). https://clinicaltrials.gov/ct2/show/NCT03653247 .

267 Vertex Pharmaceuticals Incorporated; CRISPR Therapeutics (2019). A long-term follow-up study in subjects who received CTX001. https://clinicaltrials.gov/ct2/show/NCT04208529 .

268 Traxler E.A. Yao Y. Wang Y.D. Woodard K.J. Kurita R. Nakamura Y. Hughes J.R. Hardison R.C. Blobel G.A. Li C. Weiss M.J. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition Nat. Med. 22 2016 987 990 27525524 10.1038/nm.4170 PMC5706766

269 Lux C.T. Pattabhi S. Berger M. Nourigat C. Flowers D.A. Negre O. Humbert O. Yang J.G. Lee C. Jacoby K. TALEN-mediated gene editing of HBG in human hematopoietic stem cells leads to therapeutic fetal hemoglobin induction Mol. Ther. Methods Clin. Dev. 12 2018 175 183 30705922 10.1016/j.omtm.2018.12.008 PMC6348980

270 Ye L. Wang J. Tan Y. Beyer A.I. Xie F. Muench M.O. Kan Y.W. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: an approach for treating sickle cell disease and β-thalassemia Proc. Natl. Acad. Sci. USA 113 2016 10661 10665 27601644 10.1073/pnas.1612075113 PMC5035856

271 Cai L. Bai H. Mahairaki V. Gao Y. He C. Wen Y. Jin Y.C. Wang Y. Pan R.L. Qasba A. A universal approach to correct various HBB gene mutations in human stem cells for gene therapy of beta-thalassemia and sickle cell disease Stem Cells Transl. Med. 7 2018 87 97 29164808 10.1002/sctm.17-0066 PMC5746148

272 Wattanapanitch M. Damkham N. Potirat P. Trakarnsanga K. Janan M. U-Pratya Y. Kheolamai P. Klincumhom N. Issaragrisil S. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system Stem Cell Res. Ther. 9 2018 46 29482624 10.1186/s13287-018-0779-3 PMC5828150

273 Martin R.M. Ikeda K. Cromer M.K. Uchida N. Nishimura T. Romano R. Tong A.J. Lemgart V.T. Camarena J. Pavel-Dinu M. Highly efficient and marker-free genome editing of human pluripotent stem cells by CRISPR-Cas9 RNP and AAV6 donor-mediated homologous recombination Cell Stem Cell 24 2019 821 828.e5 31051134 10.1016/j.stem.2019.04.001

274 Park S.H. Lee C.M. Dever D.P. Davis T.H. Camarena J. Srifa W. Zhang Y. Paikari A. Chang A.K. Porteus M.H. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease Nucleic Acids Res. 47 2019 7955 7972 31147717 10.1093/nar/gkz475 PMC6735704

275 Xie F. Ye L. Chang J.C. Beyer A.I. Wang J. Muench M.O. Kan Y.W. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac Genome Res. 24 2014 1526 1533 25096406 10.1101/gr.173427.114 PMC4158758

276 Song B. Fan Y. He W. Zhu D. Niu X. Wang D. Ou Z. Luo M. Sun X. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system Stem Cells Dev. 24 2015 1053 1065 25517294 10.1089/scd.2014.0347

277 Xu P. Tong Y. Liu X.Z. Wang T.T. Cheng L. Wang B.Y. Lv X. Huang Y. Liu D.P. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs Sci. Rep. 5 2015 12065 26156589 10.1038/srep12065 PMC4496796

278 Niu X. He W. Song B. Ou Z. Fan D. Chen Y. Fan Y. Sun X. Combining single strand oligodeoxynucleotides and CRISPR/Cas9 to correct gene mutations in β-thalassemia-induced pluripotent stem cells J. Biol. Chem. 291 2016 16576 16585 27288406 10.1074/jbc.M116.719237 PMC4974373

279 Liu Y. Yang Y. Kang X. Lin B. Yu Q. Song B. Gao G. Chen Y. Sun X. Li X. One-step biallelic and scarless correction of a β-thalassemia mutation in patient-specific iPSCs without Drug Selection Mol. Ther. Nucleic Acids 6 2017 57 67 28325300 10.1016/j.omtn.2016.11.010 PMC5363452

280 Allife Medical Science and Technology Co., Ltd. (2018). iHSCs with the gene correction of HBB intervent subjests with β-thalassemia mutations. https://clinicaltrials.gov/ct2/show/NCT03728322 .

281 Mettananda S. Fisher C.A. Hay D. Badat M. Quek L. Clark K. Hublitz P. Downes D. Kerry J. Gosden M. Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia Nat. Commun. 8 2017 424 28871148 10.1038/s41467-017-00479-7 PMC5583283

282 VandenDriessche T. Chuah M.K. Hemophilia gene therapy: ready for prime time? Hum. Gene Ther. 28 2017 1013 1023 28793786 10.1089/hum.2017.116

283 Franchini M. Mannucci P.M. Past, present and future of hemophilia: a narrative review Orphanet J. Rare Dis. 7 2012 24 22551339 10.1186/1750-1172-7-24 PMC3502605

284 Powell J.S. Ragni M.V. White G.C. 2nd Lusher J.M. Hillman-Wiseman C. Moon T.E. Cole V. Ramanathan-Girish S. Roehl H. Sajjadi N. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion Blood 102 2003 2038 2045 12763932 10.1182/blood-2003-01-0167

285 Kay M.A. Manno C.S. Ragni M.V. Larson P.J. Couto L.B. McClelland A. Glader B. Chew A.J. Tai S.J. Herzog R.W. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector Nat. Genet. 24 2000 257 261 10700178 10.1038/73464

286 Manno C.S. Pierce G.F. Arruda V.R. Glader B. Ragni M. Rasko J.J. Ozelo M.C. Hoots K. Blatt P. Konkle B. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response Nat. Med. 12 2006 342 347 16474400 10.1038/nm1358

287 Roth D.A. Tawa N.E. Jr. O’Brien J.M. Treco D.A. Selden R.F. Factor VIII Transkaryotic Therapy Study Group Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A N. Engl. J. Med. 344 2001 1735 1742 11396439 10.1056/NEJM200106073442301

288 Sharma R. Anguela X.M. Doyon Y. Wechsler T. DeKelver R.C. Sproul S. Paschon D.E. Miller J.C. Davidson R.J. Shivak D. In vivo genome editing of the albumin locus as a platform for protein replacement therapy Blood 126 2015 1777 1784 26297739 10.1182/blood-2014-12-615492 PMC4600017

289 Quon, D., Kuriakose, P.; Sangamo Therapeutics (2016). Ascending dose study of genome editing by zinc finger nuclease therapeutic SB-FIX in subjects with severe hemophilia B. https://clinicaltrials.gov/ct2/show/NCT02695160 .

290 Lyu C. Shen J. Wang R. Gu H. Zhang J. Xue F. Liu X. Liu W. Fu R. Zhang L. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system Stem Cell Res. Ther. 9 2018 92 29625575 10.1186/s13287-018-0839-8 PMC5889534

291 Sivalingam J. Kenanov D. Han H. Nirmal A.J. Ng W.H. Lee S.S. Masilamani J. Phan T.T. Maurer-Stroh S. Kon O.L. Multidimensional genome-wide analyses show accurate FVIII integration by ZFN in primary human cells Mol. Ther. 24 2016 607 619 26689265 10.1038/mt.2015.223 PMC4786920

292 Li H. Haurigot V. Doyon Y. Li T. Wong S.Y. Bhagwat A.S. Malani N. Anguela X.M. Sharma R. Ivanciu L. In vivo genome editing restores haemostasis in a mouse model of haemophilia Nature 475 2011 217 221 21706032 10.1038/nature10177 PMC3152293

293 Anguela X.M. Sharma R. Doyon Y. Miller J.C. Li H. Haurigot V. Rohde M.E. Wong S.Y. Davidson R.J. Zhou S. Robust ZFN-mediated genome editing in adult hemophilic mice Blood 122 2013 3283 3287 24085764 10.1182/blood-2013-04-497354 PMC3821724

294 Bergmann T. Ehrke-Schulz E. Gao J. Schiwon M. Schildgen V. David S. Schildgen O. Ehrhardt A. Designer nuclease-mediated gene correction via homology-directed repair in an in vitro model of canine hemophilia B J. Gene Med. 20 2018 e3020 29608237 10.1002/jgm.3020

295 Ohmori T. Nagao Y. Mizukami H. Sakata A. Muramatsu S.I. Ozawa K. Tominaga S.I. Hanazono Y. Nishimura S. Nureki O. Sakata Y. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice Sci. Rep. 7 2017 4159 28646206 10.1038/s41598-017-04625-5 PMC5482879

296 Guan Y. Ma Y. Li Q. Sun Z. Ma L. Wu L. Wang L. Zeng L. Shao Y. Chen Y. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse EMBO Mol. Med. 8 2016 477 488 26964564 10.15252/emmm.201506039 PMC5125832

297 He Q. Wang H.H. Cheng T. Yuan W.P. Ma Y.P. Jiang Y.P. Ren Z.H. Genetic correction and hepatic differentiation of hemophilia B-specific human induced pluripotent stem cells Chin. Med. Sci. J. 32 2017 135 144 28956740 10.24920/J1001-9294.2017.032

298 Huai C. Jia C. Sun R. Xu P. Min T. Wang Q. Zheng C. Chen H. Lu D. CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice Hum. Genet. 136 2017 875 883 28508290 10.1007/s00439-017-1801-z

299 Park C.Y. Kim D.H. Son J.S. Sung J.J. Lee J. Bae S. Kim J.H. Kim D.W. Kim J.S. Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9 Cell Stem Cell 17 2015 213 220 26212079 10.1016/j.stem.2015.07.001

300 Park C.Y. Kim J. Kweon J. Son J.S. Lee J.S. Yoo J.E. Cho S.R. Kim J.H. Kim J.S. Kim D.W. Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs Proc. Natl. Acad. Sci. USA 111 2014 9253 9258 24927536 10.1073/pnas.1323941111 PMC4078797

301 Park C.Y. Sung J.J. Choi S.H. Lee D.R. Park I.H. Kim D.W. Modeling and correction of structural variations in patient-derived iPSCs using CRISPR/Cas9 Nat. Protoc. 11 2016 2154 2169 27711053 10.1038/nprot.2016.129

302 Wagenblast E. Azkanaz M. Smith S.A. Shakib L. McLeod J.L. Krivdova G. Araújo J. Shultz L.D. Gan O.I. Dick J.E. Lechman E.R. Functional profiling of single CRISPR/Cas9-edited human long-term hematopoietic stem cells Nat. Commun. 10 2019 4730 31628330 10.1038/s41467-019-12726-0 PMC6802205

303 Genovese P. Schiroli G. Escobar G. Tomaso T.D. Firrito C. Calabria A. Moi D. Mazzieri R. Bonini C. Holmes M.C. Targeted genome editing in human repopulating haematopoietic stem cells Nature 510 2014 235 240 24870228 10.1038/nature13420 PMC4082311

304 De Ravin S.S. Reik A. Liu P.Q. Li L. Wu X. Su L. Raley C. Theobald N. Choi U. Song A.H. Targeted gene addition in human CD34 + hematopoietic cells for correction of X-linked chronic granulomatous disease Nat. Biotechnol. 34 2016 424 429 26950749 10.1038/nbt.3513 PMC4824656

305 Schiroli G. Ferrari S. Conway A. Jacob A. Capo V. Albano L. Plati T. Castiello M.C. Sanvito F. Gennery A.R. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 Sci. Transl. Med. 9 2017 eaan0820 29021165 10.1126/scitranslmed.aan0820

306 Sawamoto K. Chen H.H. Alméciga-Díaz C.J. Mason R.W. Tomatsu S. Gene therapy for mucopolysaccharidoses Mol. Genet. Metab. 123 2018 59 68 29295764 10.1016/j.ymgme.2017.12.434 PMC5986190

307 Concolino D. Deodato F. Parini R. Enzyme replacement therapy: efficacy and limitations Ital. J. Pediatr. 44 Suppl 2 2018 120 30442189 10.1186/s13052-018-0562-1 PMC6238252

308 Tomatsu S. Alméciga-Díaz C.J. Montaño A.M. Yabe H. Tanaka A. Dung V.C. Giugliani R. Kubaski F. Mason R.W. Yasuda E. Therapies for the bone in mucopolysaccharidoses Mol. Genet. Metab. 114 2015 94 109 25537451 10.1016/j.ymgme.2014.12.001 PMC4312706

309 Taylor M. Khan S. Stapleton M. Wang J. Chen J. Wynn R. Yabe H. Chinen Y. Boelens J.J. Mason R.W. Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future Biol. Blood Marrow Transplant. 25 2019 e226 e246 30772512 10.1016/j.bbmt.2019.02.012 PMC6615945

310 Schuh R.S. Poletto É. Pasqualim G. Tavares A.M.V. Meyer F.S. Gonzalez E.A. Giugliani R. Matte U. Teixeira H.F. Baldo G. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system J. Control. Release 288 2018 23 33 30170069 10.1016/j.jconrel.2018.08.031

311 Ellinwood N.M. Ausseil J. Desmaris N. Bigou S. Liu S. Jens J.K. Snella E.M. Mohammed E.E. Thomson C.B. Raoul S. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes Mol. Ther. 19 2011 251 259 21139569 10.1038/mt.2010.265 PMC3034858

312 Motas S. Haurigot V. Garcia M. Marcó S. Ribera A. Roca C. Sánchez X. Sánchez V. Molas M. Bertolin J. CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome) JCI Insight 1 2016 e86696 27699273 10.1172/jci.insight.86696 PMC5033872

313 Fu H. Dirosario J. Killedar S. Zaraspe K. McCarty D.M. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery Mol. Ther. 19 2011 1025 1033 21386820 10.1038/mt.2011.34 PMC3129800

314 Sorrentino N.C. D’Orsi L. Sambri I. Nusco E. Monaco C. Spampanato C. Polishchuk E. Saccone P. De Leonibus E. Ballabio A. Fraldi A. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA EMBO Mol. Med. 5 2013 675 690 23568409 10.1002/emmm.201202083 PMC3662312

315 Tessitore A. Faella A. O’Malley T. Cotugno G. Doria M. Kunieda T. Matarese G. Haskins M. Auricchio A. Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle Mol. Ther. 16 2008 30 37 17955027 10.1038/sj.mt.6300325

316 Gurda B.L. De Guilhem De Lataillade A. Bell P. Zhu Y. Yu H. Wang P. Bagel J. Vite C.H. Sikora T. Hinderer C. Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII Mol. Ther. 24 2016 206 216 26447927 10.1038/mt.2015.189 PMC4817811

317 Tardieu M. Zérah M. Gougeon M.L. Ausseil J. de Bournonville S. Husson B. Zafeiriou D. Parenti G. Bourget P. Poirier B. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial Lancet Neurol. 16 2017 712 720 28713035 10.1016/S1474-4422(17)30169-2

318 Laoharawee K. DeKelver R.C. Podetz-Pedersen K.M. Rohde M. Sproul S. Nguyen H.O. Nguyen T. St Martin S.J. Ou L. Tom S. Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing Mol. Ther. 26 2018 1127 1136 29580682 10.1016/j.ymthe.2018.03.002 PMC6080131

319 Harmatz, P., Heldermon, C., Wilcox, W., Whitley, C., Lau, H., and Leslie, N.; Sangamo Therapeutics (2018). Ascending dose study of genome editing by the zinc finger nuclease (ZFN) therapeutic SB-318 in subjects with MPS I. https://clinicaltrials.gov/ct2/show/NCT02702115 .

320 Burton, B., Whitley, C., Lau, H., Muenzer, J., Prada, C., and Ficcioglu, C; Sangamo Therapeutics (2017). Ascending dose study of genome editing by the zinc finger nuclease (ZFN) therapeutic SB-913 in subjects with MPS II. https://clinicaltrials.gov/ct2/show/NCT03041324 .

321 Kumaran N. Moore A.T. Weleber R.G. Michaelides M. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions Br. J. Ophthalmol. 101 2017 1147 1154 28689169 10.1136/bjophthalmol-2016-309975 PMC5574398

322 May-Simera H. Nagel-Wolfrum K. Wolfrum U. Cilia—the sensory antennae in the eye Prog. Retin. Eye Res. 60 2017 144 180 28504201 10.1016/j.preteyeres.2017.05.001

323 Jacobson S.G. Cideciyan A.V. Ratnakaram R. Heon E. Schwartz S.B. Roman A.J. Peden M.C. Aleman T.S. Boye S.L. Sumaroka A. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years Arch. Ophthalmol. 130 2012 9 24 21911650 10.1001/archophthalmol.2011.298 PMC3600816

324 Bainbridge J.W. Smith A.J. Barker S.S. Robbie S. Henderson R. Balaggan K. Viswanathan A. Holder G.E. Stockman A. Tyler N. Effect of gene therapy on visual function in Leber’s congenital amaurosis N. Engl. J. Med. 358 2008 2231 2239 18441371 10.1056/NEJMoa0802268

325 Russell S. Bennett J. Wellman J.A. Chung D.C. Yu Z.F. Tillman A. Wittes J. Pappas J. Elci O. McCague S. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial Lancet 390 2017 849 860 28712537 10.1016/S0140-6736(17)31868-8 PMC5726391

326 Maguire A.M. Simonelli F. Pierce E.A. Pugh E.N. Jr. Mingozzi F. Bennicelli J. Banfi S. Marshall K.A. Testa F. Surace E.M. Safety and efficacy of gene transfer for Leber’s congenital amaurosis N. Engl. J. Med. 358 2008 2240 2248 18441370 10.1056/NEJMoa0802315 PMC2829748

327 Sharif W. Sharif Z. Leber’s congenital amaurosis and the role of gene therapy in congenital retinal disorders Int. J. Ophthalmol. 10 2017 480 484 28393043 10.18240/ijo.2017.03.24 PMC5360787

328 Xu C.L. Cho G.Y. Sengillo J.D. Park K.S. Mahajan V.B. Tsang S.H. Translation of CRISPR genome surgery to the bedside for retinal diseases Front. Cell Dev. Biol. 6 2018 46 29876348 10.3389/fcell.2018.00046 PMC5974543

329 Allergan; Editas Medicine, Inc. (2019). Single ascending dose study in participants with LCA10. https://clinicaltrials.gov/ct2/show/NCT03872479 .

330 Coppieters F. Lefever S. Leroy B.P. De Baere E. CEP290 , a gene with many faces: mutation overview and presentation of CEP290 base Hum. Mutat. 31 2010 1097 1108 20690115 10.1002/humu.21337

331 Ruan G.X. Barry E. Yu D. Lukason M. Cheng S.H. Scaria A. CRISPR/Cas9-mediated genome editing as a therapeutic approach for Leber congenital amaurosis 10 Mol. Ther. 25 2017 331 341 28109959 10.1016/j.ymthe.2016.12.006 PMC5368591

332 Maeder M.L. Stefanidakis M. Wilson C.J. Baral R. Barrera L.A. Bounoutas G.S. Bumcrot D. Chao H. Ciulla D.M. DaSilva J.A. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10 Nat. Med. 25 2019 229 233 30664785 10.1038/s41591-018-0327-9

333 Sanjurjo-Soriano C. Kalatzis V. Guiding lights in genome editing for inherited retinal disorders: implications for gene and cell therapy Neural Plast. 2018 2018 5056279 29853845 10.1155/2018/5056279 PMC5964415

334 Xu C.L. Park K.S. Tsang S.H. CRISPR/Cas9 genome surgery for retinal diseases Drug Discov. Today. Technol. 28 2018 23 32 30205877 10.1016/j.ddtec.2018.05.001 PMC6136254

335 Zhang Z.Y. Thrasher A.J. Zhang F. Gene therapy and genome editing for primary immunodeficiency diseases Genes Dis. 7 2019 38 51 32181274 10.1016/j.gendis.2019.07.007 PMC7063425

336 Booth C. Romano R. Roncarolo M.G. Thrasher A.J. Gene therapy for primary immunodeficiency Hum. Mol. Genet. 28 R1 2019 R15 R23 31297531 10.1093/hmg/ddz170

337 VanLith C.J. Guthman R.M. Nicolas C.T. Allen K.L. Liu Y. Chilton J.A. Tritz Z.P. Nyberg S.L. Kaiser R.A. Lillegard J.B. Hickey R.D. Ex vivo hepatocyte reprograming promotes homology-directed DNA repair to correct metabolic disease in mice after transplantation Hepatol. Commun. 3 2019 558 573 30976745 10.1002/hep4.1315 PMC6442694

338 Vaidyanathan S. Salahudeen A.A. Sellers Z.M. Bravo D.T. Choi S.S. Batish A. Le W. Baik R. de la O S. Kaushik M.P. High-efficiency, selection-free gene repair in airway stem cells from cystic fibrosis patients rescues CFTR function in differentiated epithelia Cell Stem Cell 26 2020 161 171.e4 31839569 10.1016/j.stem.2019.11.002 PMC10908575

339 Nissanka N. Moraes C.T. Mitochondrial DNA heteroplasmy in disease and targeted nuclease-based therapeutic approaches EMBO Rep. 21 2020 e49612 32073748 10.15252/embr.201949612 PMC7054667

340 Zekonyte U. Bacman S.R. Moraes C.T. DNA-editing enzymes as potential treatments for heteroplasmic mtDNA diseases J. Intern. Med. 287 2020 685 697 32176378 10.1111/joim.13055 PMC7260085

341 Pankowicz F.P. Barzi M. Legras X. Hubert L. Mi T. Tomolonis J.A. Ravishankar M. Sun Q. Yang D. Borowiak M. Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia Nat. Commun. 7 2016 12642 27572891 10.1038/ncomms12642 PMC5013601

342 Villiger L. Grisch-Chan H.M. Lindsay H. Ringnalda F. Pogliano C.B. Allegri G. Fingerhut R. Häberle J. Matos J. Robinson M.D. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice Nat. Med. 24 2018 1519 1525 30297904 10.1038/s41591-018-0209-1

343 Lu T. Yang B. Wang R. Qin C. Xenotransplantation: current status in preclinical research Front. Immunol. 10 2020 3060 32038617 10.3389/fimmu.2019.03060 PMC6989439

344 Ferrari S. Jacob A. Beretta S. Unali G. Albano L. Vavassori V. Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking Nat. Biotechnol. 2020 10.1038/s41587-020-0551-y PMC7610558 32601433

Acknowledgments

We thank Anita Rijneveld for reading and commenting on the original manuscript. This work has received funding from Texnet , 10.13039/501100009622 Zeldzame Ziekten Fonds /WE Foundation, 10.13039/100016062 Metakids (project number 2018-082), and Stofwisselkracht . The collaboration project is co-funded by the PPP Allowance made available by 10.13039/100016036 Health∼Holland , 10.13039/100016036 Top Sector Life Sciences & Health , to the Prinses Beatrix Spierfonds to stimulate public-private partnerships (project numbers LSHM17075 and LSHM19015).